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ABSTRACT 
 
Organic anion-transporting polypeptides (OATPs) are multispecific transporters that 
mediate the uptake of numerous drugs and xenobiotics into cells. Alterations in the function of 
the liver-specific OATP1B1 and OATP1B3 have been shown to affect the disposition of drugs 
throughout the body. It has been proposed that new drug candidates should be screened for 
possible OATP inhibition using a prototypical substrate such as estradiol-17β-glucuronide. 
However, there is evidence that OATPs may have multiple binding sites, and therefore screening 
with a single compound may be ineffective. Therefore, I tested the hypothesis that OATP1B3 has 
multiple overlapping but distinct binding sites, which are affected in substrate-dependent ways. 
This hypothesis was tested via two specific aims: 1) to identify and characterize substrate-
dependent effects of plant compounds on OATP1B3-mediated transport, and 2) to identify 
regions of OATP1B3 involved in the binding and/or translocation of individual model substrates. 
 
In the first specific aim, interacting compounds were identified by screening a library of 
plant compounds for inhibition or stimulation of OATP-mediated uptake of two model 
substrates. Completion of this specific aim identified two structurally similar compounds that 
produce substrate-dependent effects on OATP1B3-mediated transport. These compounds 
stimulate transport of estrone-3-sulfate by increasing substrate affinity. However, the compounds 
either inhibit or have no effect on the uptake of estradiol-17β-glucuronide. These results 
demonstrate that estrone-3-sulfate and estradiol-17β-glucuronide have distinct binding sites on 
OATP1B3. 
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In specific aim two, thirty-three amino acids in the first transmembrane domain and 
extracellular loop of OATP1B3 were individually mutated to cysteines, and I determined the 
effect of these mutations on the transport of estradiol-17β-glucuronide and estrone-3-sulfate. 
Five of the cysteine-substituted OATP1B3 mutants produced different effects on transporter 
function depending upon the substrate tested. These results suggest that this region of OATP1B3 
is involved in the recognition and translocation of individual model substrates.  
 
This dissertation demonstrates that OATP1B3 has distinct binding sites for estradiol-17β-
glucuronide and estrone-3-sulfate. Furthermore, it shows that transport of these two model 
substrates is affected in different ways by the same compounds. This knowledge can be used to 
improve screening of drug candidates to prevent adverse drug-drug interactions prior to the 
occurrence of adverse events. 
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Chapter 1 
Background and Significance 
 
1.1: Drug Absorption and Distribution 
 
The field of pharmacology, which is the study of drugs, can be broadly divided into two 
disciplines: pharmacokinetics and pharmacodynamics. These disciplines have been described as 
the study of what drugs do to the body (pharmacodynamics), and what the body does to drugs 
(pharmacokinetics). The pharmacokinetics of a drug describes its disposition throughout the 
body and are determined by four factors commonly described by the acronym ADME: 
absorption, distribution, metabolism and excretion.  
 
The first step, absorption, involves entry of the drug into the bloodstream. This step is not 
always necessary: a drug may exert its effect where it is applied (e.g. the surface of the skin) or 
absorption may be bypassed by injecting the drug directly into the bloodstream. However, to 
exert their effect, most drugs must enter the bloodstream by passing through one of the barriers 
that protect the body from the outside world. The most common means by which a drug is 
absorbed is by passing through the intestinal epithelium after oral administration, although drugs 
may also be absorbed through the skin or lungs, or may be injected into muscle, peritoneal fluid, 
or under the skin. The distribution of drug involves its delivery into tissues from the 
bloodstream. The site of action for a drug is known as the target tissue, but this is rarely the only 
tissue exposed. Most drugs are converted into other compounds after entering the body through 
enzyme-catalyzed metabolism. The metabolites generally have different chemical characteristics 
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than the parent drug and may be active (having the desired effect) or, more commonly, be easier 
for the body to excrete. Excretion, the final component of drug disposition, is the elimination of 
drugs from the body. The most common routes of excretion are through the kidney (into urine) 
or the liver (into bile eliminated through feces). 
 
With the exception of metabolism, all steps of drug disposition involve passage of the 
drug or its metabolites through cell membranes. Whereas some small, hydrophobic, and 
uncharged drugs may passively diffuse through cell membranes, many drugs and other 
xenobiotics require transporter proteins to mediate their translocation through the cell membrane. 
Therefore, transporters are essential to the pharmacokinetics of many drugs.  
 
1.2: Transporters Involved in Drug Absorption, Distribution and 
Elimination 
 
There are two major superfamilies of multispecific drug transporters: solute carrier (SLC) 
transporters and ATP-binding cassette (ABC) transporters. Many of these transporters are 
capable of bi-directional transport. In practice, however, they act in opposition, with SLC 
transporters mediating uptake of substrates into cells whereas ABC transporters pump substrates 
out of cells. SLC transporters involved in drug influx include the organic cation transporters 
(OCTs), organic anion transporters (OATs), organic cation/carnitine transporters (OCTNs), 
organic anion transporting polypeptides (OATPs), petptide transporters (PEPTs), 
monocarboxylate transporters (MCTs, SMCTs), nucleoside transporters (CNTs, ENTs) and bile 
acid transporters (NTCP, ASBT) (You and Morris, 2007). Drug efflux is mediated by ABC 
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transporters, such as the multidrug resistance protein (MDR, also known as P-glycoprotein), 
multidrug resistance-associated proteins (MRPs), breast cancer resistance proteins (BCRP), and 
the bile acid transporter BSEP (You and Morris, 2007). This dissertation focuses on four 
transporters that are involved in drug absorption and first-pass clearance from the blood stream: 
OATP1A2, OATP1B1, OATP1B3, and OATP2B1. 
 
1.3: The Organic Anion Transporting Polypetide (OATP) Superfamily of 
Drug Uptake Transporters 
 
Organic anion transporting polypeptides (OATPs in humans, Oatps in other species) are 
multispecific transporters expressed on epithelia throughout the body that mediate the cellular 
uptake of a broad range of substrates.  
 
1.3.1:  Nomenclature 
 
Originally classified as superfamily SLC21A, the genes encoding the OATP proteins were 
reclassified as the SLCO (solute carrier family of the OATPs) superfamily in 2004, to create a 
standard nomenclature based on phylogenetic relationships (Hagenbuch and Meier, 2004). The 
eleven members of the OATP superfamily in humans are classified into six families based on a 
40% amino acid identity, and further divided into 10 subfamilies based on a 60% amino acid 
identity. The nomenclature consists of OATP followed by the family number, subfamily letter, 
and a number based on the historical order of identification. For example, OATP1A2 is a human  
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transporter in family 1, subfamily A, which was the second OATP1A family member discovered. 
The gene symbols are named with the same system, substituting SLCO for OATP.  
 
A significant amount of gene duplication and divergence has occurred in this 
superfamily. OATP1A2 has 5 rodent orthologs: Oatp1a1, Oatp1a3 (in rats only), Oatp1a4, 
Oatp1a5 and Oatp1a6, whereas OATP1B1 and OATP1B3 have a single rodent ortholog, 
Oatp1b2. The other OATPs and their rodent orthologs are OATP1C1 (Oatp1c1), OATP2A1 
(Oatp2a1), OATP2B1 (Oatp2b1), OATP3A1 (Oatp3a1), OATP4A1 (Oatp4a1), OATP4C1, 
OATP5A1, and OATP6A1 (Oatp6b1, Oatp6c1, and Oatp6d1). The phylogenetic tree for human 
OATPs and their rodent orthologs are shown in Figure 1-1. The best characterized OATPs 
belong to families 1 and 2, and include OATP1A2, OATP1B1, OATP1B3, and OATP2B1. 
 
1.3.2:  Tissue Distribution 
 
1.3.2a:  Normal Expression 
 
OATP1A2, the first human OATP identified, is expressed widely throughout the body. 
Northern blots show that the highest mRNA expression is in the brain, liver, lung, kidney and 
testes (Kullak-Ublick et al., 1995; Steckelbroeck et al., 2004). Protein has been localized to the 
brush border membrane of enterocytes (Glaeser et al., 2007), to cholangiocytes in the liver (Lee 
et al., 2005), at the apical membrane of distal nephrons in the kidney (Lee et al., 2005), and at the 
luminal membrane of endothelial cells of brain capillaries (Bronger et al., 2005). OATP1B1 and 
OATP1B3 are both thought to be exclusively expressed at the basolateral membrane of  
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Figure 1-1: 
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Figure 1-1: 
 
Phylogenetic tree of human, rat and mouse OATPs/Oatps. Oatps/OATPs with amino acid 
sequence identities ≥ 40% among each other belong to the same OATP family (e.g. OATP1, 
OATP2, OATP3, OATP4, OATP5, OATP6). Proteins with amino acid sequence identities ≥ 
60% are grouped into subfamilies and denoted with a capital letter after the family number (e.g. 
OATP1A, OATP1B, OATP1C, OATP2A, OATP2B, etc.). Individual proteins (genes) are 
continuously numbered according to the chronology of their identification. The “Oatp” 
(rodents)/“OATP” (human) symbols denote proteins, whereas the “Slco”/“SLCO” symbols 
indicate the respective genes. Mouse Oatps are indicated by “m”. Only the families OATP1 to 
OATP6 are indicated, since only these six families contain human OATPs. Reproduced with 
kind permission from Springer Science+Business Media: (Hagenbuch and Meier, 2004). 
	  
	  
	   7	  
hepatocytes under normal physiological conditions (Abe et al., 1999; Konig et al., 2000a; Abe et 
al., 2001) al., 2001); (Hsiang et al., 1999; Konig et al., 2000b; Kullak-Ublick et al., 2001; Cui et 
al., 2003). OATP1B1 has higher mRNA levels in total liver than does OATP1B3 (Michalski et 
al., 2002; Briz et al., 2006); however, it is expressed in hepatocytes throughout the lobule, while 
OATP1B3 is primarily expressed around the central vein (Konig et al., 2000b). OATP1C1 
protein is expressed at the basolateral membrane of choroid plexus epithelial cells (Roberts et al., 
2008) and in the Leydig cells of the testes (Pizzagalli et al., 2002). 
 
OATP2A1 is ubiquitously expressed throughout the body, with mRNA identified in 
brain, colon, heart, kidney, liver, lung, ovary, pancreas, placenta, prostate, skeletal muscle, 
spleen, and small intestine (Schuster, 2002; Nomura et al., 2004; Nomura et al., 2005). 
OATP2B1 is also widely expressed throughout the body (Tamai et al., 2000; Kullak-Ublick et 
al., 2001), with protein localized to the basolateral membrane of hepatocytes (Kullak-Ublick et 
al., 2001), the apical membrane of enterocytes (Kobayashi et al., 2003), the basolateral 
membrane of syncytiotrophoblasts in the placenta (St-Pierre et al., 2002), and the luminal 
membrane of endothelial cells of the blood-brain barrier (Bronger et al., 2005), as well as in 
epidermal keratinocytes (Schiffer et al., 2003), in vascular endothelial cells in the heart (Grube et 
al., 2006b), and in the myoepithelium surrounding ductal epithelial cells in human mammary 
glands (Pizzagalli et al., 2003).  
 
The less well studied OATP3A1 and OATP4A1 are also expressed at the mRNA level in 
a wide variety of tissues (Tamai et al., 2000; Fujiwara et al., 2001; Adachi et al., 2003; Huber et 
al., 2007). OATP4C1 mRNA has only been detected in kidney (Mikkaichi et al., 2004), whereas 
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OATP5A1 expression has not yet been determined. OATP6A1 mRNA has highest levels in the 
testes, although it is also expressed at low levels in spleen, brain, fetal brain, and placenta 
(Suzuki et al., 2003; Lee et al., 2004). 
 
1.3.2b:  Dysregulated Expression 
 
Normal OATP expression patterns are altered in a wide variety of cancers. OATP1A2 is 
expressed at decreased levels in colon polyps and cancer tissue when compared to healthy colon 
tissue (Ballestero et al., 2006). Conversely, OATP1A2 expression is significantly higher in 
malignant breast tissue than in adjacent non-malignant tissue (Meyer zu Schwabedissen et al., 
2008). Expression levels of both liver-specific proteins OATP1B1 and OATP1B3 are decreased 
in hepatocellular carcinomas (Cui et al., 2003; Zollner et al., 2005; Tsuboyama et al., 2010) and 
adenomas (Vander Borght et al., 2005). OATP1B3, which is normally restricted to hepatocytes, 
is also expressed in many different tumors and cancer cell lines, including gastric, colon, and 
pancreatic cancers (Abe et al., 2001; Lee et al., 2008), lung cancer (Monks et al., 2007), breast 
cancer (Muto et al., 2007), and prostate cancer (Hamada et al., 2008). Table 1-1 shows the 
dysregulated expression patterns of the normally liver-specific OATP1B1 and OATP1B3. 
 
1.3.2c:  Physiological Consequences of Expression 
 
The expression pattern of OATPs illustrates their potential involvement in drug 
absorption and distribution. Both OATP1A2 and OATP2B1 are expressed on the apical 
membrane of enterocytes, where they may mediate the absorption of drugs and other xenobiotics 
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from the intestinal lumen. OATP1B1, OATP1B3, and OATP2B1 are all expressed on the 
basolateral membrane of hepatocytes, and are involved in the first-pass clearance of many drugs 
from the bloodstream. Figure 1-2 illustrates the role these OATP family members may play in 
drug absorption and first-pass clearance from the blood-stream. OATP1A2 is also expressed in 
liver, but is localized to cholangiocytes, where it may be involved in reabsorbing xenobiotics that 
would otherwise be excreted through the bile. Similarly, OATP1A2 is expressed at the apical 
membrane of distal nephrons in the kidney, where it could be involved in the secretion of 
xenobiotics into the urine or, conversely, could mediate the reabsorption of xenobiotics from the 
urine. The expression of OATP1A2 and OATP2B1 in the endothelial cells of brain capillaries 
also suggests that these proteins could play a role in either maintaining or bypassing the blood-
brain barrier. Finally, OATP2B1 is expressed in epithelial cells in placenta and mammary glands, 
and could be involved in bypassing or maintaining the fetal-maternal blood barrier and blood-
milk barrier. 
 
The abnormal expression of OATPs in many cancer types may also have physiological 
consequences. OATPs transport numerous hormones and their conjugates, which could provide a 
survival benefit to hormone-dependent cancers. Additionally, as will be described in the 
following section, OATPs are capable of transporting a variety of anti-cancer drugs. 
Theoretically, this ability could be taken advantage of to better target chemotherapeutic drugs to 
cancer tissues. Of particular interest is the expression of the normally hepatocyte-specific 
OATP1B3 in numerous cancer tissues. By improving OATP1B3-mediated transport of 
anticancer drugs, those drugs could be better directed into the cancer tissues as well as into the 
slowly dividing hepatocytes, where their toxicity would be much lower.  
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Table 1-1:	  Expression of OATP1B1 and OATP1B3 in cancer tissues. Modified 
from Obaidat et al. (2012). 
 
 
OATP  
 
Cancer tissue expression 
 
Reference 
 
OATP1B1 
 
Reduced in Hepatocellular  
carcinoma 
 
 
(Cui et al., 2003; Vander Borght et al., 
2005; Zollner et al., 2005; Libra et al., 
2006; Monks et al., 2007; Tsuboyama et 
al., 2010) 
 
OATP1B3 
 
Reduced in Hepatocellular  
carcinoma 
 
Expressed in: 
 
Colorectal adenocarcinoma tissues 
Non-small cell lung tumors 
Prostate cancer tissue 
Invasive ductal carcinoma breast  
cells 
Cell lines of stomach, colon,  
pancreatic and gall bladder cancers 
 
(Vavricka et al., 2004) 
 
 
 
 
(Lee et al., 2008) 
(Monks et al., 2007) 
(Hamada et al., 2008; Wright et al., 2011) 
(Muto et al., 2007) 
 
(Abe et al., 1999) 
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Figure 1-2: 
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Figure 1-2: 
 
OATPs involved in xenobiotic absorption and first-pass clearance. Xenobiotics may be 
absorbed into enterocytes from the intestinal lumen through OATP1A2- or OATP2B1-mediated 
transport. Absorbed xenobiotics enter the portal blood from the enterocytes through 
uncharacterized transporters. Portal blood then flows through the liver, where xenobiotics may 
be taken up into hepatocytes through OATP1B1-, OATP1B3- or OATP2B1-mediated transport. 
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 1.3.3:  Substrate Specificity 
 
OATPs mediate the uptake of a wide range of structurally diverse, amphipathic 
compounds, both endogenous and exogenous. Among the endogenous OATP substrates are bile 
acids, conjugated steroids, thyroid hormones, and linear and cyclic peptides. Xenobiotic 
substrates include mushroom toxins, the cholesterol-lowering statins, sartans, numerous 
antibiotics, and some anticancer drugs. Selected substrates of OATP1A2, OATP1B1, OATP1B3, 
and OATP2B1 are listed in Tables 1-2 through 1-5. 
 
OATPs have a partially overlapping yet distinct substrate specificity. For example, all 
four proteins described above transport the model substrates estrone-3-sulfate and 
bromosulfophthalein; fluvastatin is transported by OATPs 1B1, 1B3, and 2B1; and methotrexate 
is transported by OATPs 1A2, 1B1, and 1B3, however cholecystokinin-octapeptide (CCK8) is 
selectively transported by OATP1B3. The diverse range of substrates for OATPs suggests the 
presence of multiple binding sites. Indeed, OATP1B1-mediated transport of estrone-3 sulfate has 
biphasic saturation kinetics, suggesting the presence of both a high-affinity, low-capacity binding 
site and a low-affinity, high-capacity binding site (Tamai et al., 2001; Noe et al., 2007; Gui and 
Hagenbuch, 2009). Similarly, it has been shown that OATP4C1 has distinct binding sites for 
estrone-3-sulfate and digoxin (Yamaguchi et al., 2010), and that rat Oatp1a4 has at least two 
distinct binding sites, with estradiol-17β-glucuronide being handled differently than digoxin or 
taurocholate (Sugiyama et al., 2002). In addition, compounds may have inhibitory, stimulatory, 
or no effect on OATP-mediated transport, depending on the model substrate used. Clotrimazole 
stimulates transport of estradiol-17β-glucuronide by OATP1B3, whereas it inhibits transport of 
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Table 1-2: Selected Substrates of OATP1A2. Modified from Roth et al. (Submitted). 
 
 Substrates References 
  
Acebutolol (Kato et al., 2009) 
Atenolol (Kato et al., 2009) 
Atrasentan (Katz et al., 2006) 
Bamet-R2 (Briz et al., 2002) 
Bamet-UD2 (Briz et al., 2002) 
Bilirubin (Briz et al., 2003) 
BQ-123 (Kullak-Ublick et al., 2001) 
Bromosulfophthalein (Kullak-Ublick et al., 1995) 
Celiprolol (Kato et al., 2009) 
Chlorambucil-taurocholate (Kullak-Ublick et al., 1997) 
Cholate (Kullak-Ublick et al., 1995; Meier et 
al., 1997) 
Ciprofloxacin (Maeda et al., 2007) 
CRC220 (Meier et al., 1997) 
Darunavir (Hartkoorn et al., 2010) 
Dehydroepiandrosterone-3-sulfate  (Kullak-Ublick et al., 1998) 
Deltorphin II (Gao et al., 2000) 
[D-penicillamine2,5]enkephalin  (Gao et al., 2000) 
Enoxacin (Maeda et al., 2007) 
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Epicatechin gallate (Roth et al., 2011b) 
Epigallocatechin gallate (Roth et al., 2011b) 
Erythromycin (Franke et al., 2008) 
Estradiol-17β-glucuronide (Meier et al., 1997; Kullak-Ublick et 
al., 2001; Briz et al., 2003) 
Estrone-3-sulfate (Lee et al., 2005) 
Fexofenadine (Cvetkovic et al., 1999) 
Gatifloxacin (Maeda et al., 2007) 
Gd-B20790 (Pascolo et al., 1999) 
Glycocholate (Kullak-Ublick et al., 1995; Meier et 
al., 1997; Kullak-Ublick et al., 2001) 
Hydroxyurea (Walker et al., 2011) 
Imatinib (Hu et al., 2008) 
Labetalol (Kato et al., 2009) 
Levofloxacin (Maeda et al., 2007) 
Lomefloxacin (Maeda et al., 2007) 
Lopinavir (Hartkoorn et al., 2010) 
Methotrexate (Badagnani et al., 2006) 
Microcystin (Fischer et al., 2005) 
Nadolol (Kato et al., 2009) 
Norfloxacin (Maeda et al., 2007) 
Ouabain (Bossuyt et al., 1996) 
Pitavastatin (Fujino et al., 2005) 
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Prostaglandin E2 (Kullak-Ublick et al., 2001) 
Reverse triiodothyronine (rT3) (Fujiwara et al., 2001) 
Rocuronium (van Montfoort et al., 1999) 
Rosuvastatin (Ho et al., 2006) 
Saquinavir (Su et al., 2004) 
Sotalol (Kato et al., 2009) 
Talinolol (Shirasaka et al., 2010) 
Taurocholate (Kullak-Ublick et al., 1995) 
Taurochenodeoxycholate (Kullak-Ublick et al., 1995) 
Tauroursodeoxycholate (Kullak-Ublick et al., 1995) 
Thyroxine (T4) (Fujiwara et al., 2001) 
Tebipenem pivoxil (Kato et al., 2010) 
TR-14035 (Tsuda-Tsukimoto et al., 2006) 
Triiodothyronine (T3) (Fujiwara et al., 2001) 
Unoprostone metabolite (Gao et al., 2005) 
 
 
Bamet-R2: cis-diammine-chloro-cholylglycinate-platinum(II); Bamet-UD2: cis-diammine-
bisursodeoxycholate-platinum(II); BQ-123: cyclic pentapeptide endothelin receptor antagonist; 
CRC220: peptidomimetic thrombin inhibitor; TR-14035: a4b1/a4b7 integrin dual antagonist  
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Table 1-3: Selected Substrates of OATP1B1. Modified from Roth et al. (submitted). 
 
 Substrates References 
  
Arsenic (arsenite, arsenate) (Lu et al., 2006) 
Atorvastatin (Lau et al., 2007) 
Atrasentan (Katz et al., 2006) 
Bamet-R2 (Briz et al., 2002) 
Bamet-UD2 (Briz et al., 2002) 
Benzylpenicillin (Tamai et al., 2000) 
BDE47 (Pacyniak et al., 2010) 
BDE99 (Pacyniak et al., 2010) 
BDE153 (Pacyniak et al., 2010) 
Bilirubin (Briz et al., 2003) 
Bisglucuronosyl bilirubin (Cui et al., 2001) 
Bosentan (Treiber et al., 2007) 
BQ-123 (Kullak-Ublick et al., 2001) 
Bromosulfophthalein (Cui et al., 2001; Kullak-Ublick et 
al., 2001) 
Caspofungin (Sandhu et al., 2005) 
Cefazolin (Nakakariya et al., 2008) 
Cefditoren (Nakakariya et al., 2008) 
Cefoperazone (Nakakariya et al., 2008) 
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Cerivastatin (Shitara et al., 2003) 
Cholate (Cui et al., 2001) 
[D-Ala2, D-Leu5]enkephalin  (Nozawa et al., 2003) 
Darunavir (Hartkoorn et al., 2010) 
Dehydroepiandrosterone-3-sulfate 
(DHEAS) 
(Abe et al., 1999; Hsiang et al., 1999; 
Abe et al., 2001; Cui et al., 2001; 
Kullak-Ublick et al., 2001) 
Demethylphalloin (Meier-Abt et al., 2004) 
[D-penicillamine2,5]enkephalin (DPDPE) (Abe et al., 2001) 
Eltrombopag (Takeuchi et al., 2011) 
Enalapril (Liu et al., 2006) 
Estradiol-17β-glucuronide (Abe et al., 1999; Konig et al., 
2000b; Tamai et al., 2000; Cui et al., 
2001; Kullak-Ublick et al., 2001; 
Nakai et al., 2001; Tamai et al., 
2001; Hirano et al., 2004) 
Estrone-3-sulfate (Cui et al., 2001; Hirano et al., 2004) 
 (Tamai et al., 2001; Noe et al., 2007) 
Ezetimibe glucuronide (Oswald et al., 2008) 
Fluvastatin (Kopplow et al., 2005; Noe et al., 
2007) 
Gimatecan (Oostendorp et al., 2009) 
Glycocholate (Kullak-Ublick et al., 2001) 
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Glycoursodeoxycholate (Maeda et al., 2006b) 
Hydroxyurea (Walker et al., 2011) 
Leukotriene C4 (Abe et al., 1999) 
Leukotriene E4 (Abe et al., 1999) 
Lopinavir (Hartkoorn et al., 2010) 
Mesalazine (Konig, 2011) 
Methotrexate (Abe et al., 2001) 
Microcystein (Fischer et al., 2005) 
Monoglyucuronosyl bilirubin (Cui et al., 2001) 
Mycophenolic acid-7-O-glucuronide (Picard et al., 2010) 
Nafcillin (Nakakariya et al., 2008) 
Olmesartan (Nakagomi-Hagihara et al., 2006; 
Yamada et al., 2007) 
Phalloidin (Fehrenbach et al., 2003; Meier-Abt 
et al., 2004) 
Pitavastatin (Hirano et al., 2004; Fujino et al., 
2005) 
Pravastatin (Hsiang et al., 1999; Nakai et al., 
2001; Sasaki et al., 2002) 
Prostaglandin E2 (Abe et al., 1999; Tamai et al., 2000; 
Kullak-Ublick et al., 2001) 
Rifampicin (Vavricka et al., 2002; Tirona et al., 
2003) 
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Rosuvastatin (Ho et al., 2006) 
Saquinavir (Hartkoorn et al., 2010) 
Simvastatin acid (Pasanen et al., 2006) 
SN-38 (Nozawa et al., 2005a) 
Taurocholate (Abe et al., 1999; Hsiang et al., 1999; 
Abe et al., 2001; Cui et al., 2001; 
Kullak-Ublick et al., 2001) 
Tauroursodeoxycholate (Maeda et al., 2006b) 
Temocapril (Maeda et al., 2006a) 
Thromboxane B2 (Abe et al., 1999) 
Thyroxine (T4) (Abe et al., 1999) 
Torasemide (Vormfelde et al., 2008; Werner et 
al., 2008) 
Triiodothyronine (T3) (Abe et al., 1999) 
Troglitazone sulfate (Nozawa et al., 2004b) 
Valsartan (Yamashiro et al., 2006) 
 
 
Bamet-R2: cis-diammine-chloro-cholylglycinate-platinum(II); Bamet-UD2: cis-diammine-
bisursodeoxycholate-platinum(II); BDE47: 2,2’,4,4’-Tetrabromodiphenyl ether; BDE99: 
2,2’,4,4’,5-pentabromodiphenyl ether; BDE153: 2,2’,4,4’,5,5’-hexabromodiphenyl ether; BQ-
123: cyclic pentapeptide endothelin receptor antagonist; SN-38: 7-ethyl-10-
hydroxycamptothecin (active metabolite of irinotecan) 
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Table 1-4: Selected Substrates of OATP1B3. Modified from Roth et al. (submitted). 
 
 Substrates References 
  
Amanitin (Letschert et al., 2006) 
Atrasentan (Katz et al., 2006) 
Benzylpenicillin (Penicillin G) (Letschert et al., 2006) 
BDE47 (Pacyniak et al., 2010) 
BDE99 (Pacyniak et al., 2010) 
BDE153 (Pacyniak et al., 2010) 
Bilirubin (Briz et al., 2003) 
Bosentan (Treiber et al., 2007) 
BQ-123 (Kullak-Ublick et al., 2001) 
Bromosulfophthalein (Kullak-Ublick et al., 2001) 
Cefadroxil (Nakakariya et al., 2008) 
Cefazolin (Nakakariya et al., 2008) 
Cefditoren (Nakakariya et al., 2008) 
Cefmetazole (Nakakariya et al., 2008) 
Cefoperazone (Nakakariya et al., 2008) 
Cephalexin (Nakakariya et al., 2008) 
CDCA-NBD (Yamaguchi et al., 2006) 
Cholate (Briz et al., 2006) 
Cholecystokinin octapeptide (CCK-8) (Ismair et al., 2001; Hirano et al., 
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2004) 
Cholyl-glycylamido-fluorescein (CGamF) (Annaert et al., 2010) 
Dehydroepiandrosterone-3-sulfate 
(DHEAS) 
(Konig et al., 2000a; Cui et al., 2001; 
Kullak-Ublick et al., 2001) 
Deltorphin II (Kullak-Ublick et al., 2001) 
Demethylphalloin (Meier-Abt et al., 2004) 
Diclofenac (Kindla et al., 2011) 
Digoxin (Kullak-Ublick et al., 2001) 
Docetaxel (Smith et al., 2005a) 
[D-penicillamine2,5]enkephalin (DPDPE) (Kullak-Ublick et al., 2001) 
Enalapril (Liu et al., 2006) 
Epicatechin gallate (Roth et al., 2011b) 
Epigallocatechin gallate (Roth et al., 2011b) 
Erythromycin (Franke et al., 2008) 
Estradiol-17β-glucuronide (Konig et al., 2000a; Cui et al., 2001; 
Hirano et al., 2004) 
Estrone-3-sulfate (Kullak-Ublick et al., 2001; Nozawa 
et al., 2004b; Nozawa et al., 2005b) 
Fexofenadine (Shimizu et al., 2005) 
Fluvastatin (Kopplow et al., 2005) 
Glutathione (Briz et al., 2006) 
Glycocholate (Kullak-Ublick et al., 2001; Briz et 
al., 2006) 
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Glycoursodeoxycholate (Maeda et al., 2006b) 
Hydroxyurea (Walker et al., 2011) 
Imatinib (Hu et al., 2008) 
Leukotriene C4 (Konig et al., 2000a; Kullak-Ublick 
et al., 2001) 
Mesalazine (Konig, 2011) 
Methotrexate (Abe et al., 2001) 
Microcystin (Fischer et al., 2005; Komatsu et al., 
2007) 
Monoglyucuronosyl bilirubin (Cui et al., 2001) 
Mycophenolic acid-7-O-glucuronide (Picard et al., 2010) 
Nafcillin (Nakakariya et al., 2008) 
Olmesartan (Nakagomi-Hagihara et al., 2006; 
Yamada et al., 2007) 
Ouabain (Kullak-Ublick et al., 2001) 
Paclitaxel (Smith et al., 2005a) 
Phalloidin (Meier-Abt et al., 2004) 
Pitavastatin (Hirano et al., 2004; Fujino et al., 
2005) 
Rifampicin (Vavricka et al., 2002; Tirona et al., 
2003) 
Ro 48-5033 (Treiber et al., 2007) 
Rosuvastatin (Ho et al., 2007) 
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S-8921G (Sakamoto et al., 2008) 
Saquinavir (Hartkoorn et al., 2010) 
Taurocholate (Abe et al., 2001; Kullak-Ublick et 
al., 2001; Letschert et al., 2004; Briz 
et al., 2006) 
Taurochenodeoxycholate  (Briz et al., 2006) 
Taurodeoxycholate  (Briz et al., 2006) 
Tauroursodeoxycholate  (Maeda et al., 2006b) 
Telmisartan (Ishiguro et al., 2006) 
Thyroxine (T4) (Kullak-Ublick et al., 2001) 
TR-14035 (Tsuda-Tsukimoto et al., 2006) 
Triiodothyronine (T3) (Abe et al., 2001; Kullak-Ublick et 
al., 2001) 
Valsartan (Yamashiro et al., 2006) 
 
 
BDE47: 2,2’,4,4’-Tetrabromodiphenyl ether; BDE99: 2,2’,4,4’,5-pentabromodiphenyl ether; 
BDE153: 2,2’,4,4’,5,5’-hexabromodiphenyl ether; BQ-123: cyclic pentapeptide endothelin 
receptor antagonist; CDCA-NBD: chenodeoxycholyl-(Ne-NBD)-lysine; Ro 48-5033: Bosentan 
metabolite; S-8921G: methyl 1-(3,4-dimethoxyphenyl)-(3-ethylvaleryl)-4-hydroxy-6,7,8-
trimethoxy-2-naphthoate glucuronide (inhibitor of the ilial apical sodium-dependent bile acid 
transporter); TR-14035: a4b1/a4b7 integrin dual antagonist  
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Table 1-5: Selected Substrates of OATP2B1 Modified from Roth et al. (submitted). 
 
 Substrates References 
Aliskiren (Vaidyanathan et al., 2008) 
Atorvastatin (Grube et al., 2006b) 
Benzylpenicillin (Tamai et al., 2000) 
BDE47 (Pacyniak et al., 2010) 
BDE99 (Pacyniak et al., 2010) 
BDE153 (Pacyniak et al., 2010) 
Bosentan (Treiber et al., 2007) 
Bromosulfophthalein (Kullak-Ublick et al., 2001) 
Dehydroepiandrosterone-3-sulfate 
(DHEAS) 
(Pizzagalli et al., 2003) 
Eltrombopag (Takeuchi et al., 2011) 
Estrone-3-sulfate (Tamai et al., 2001; Pizzagalli et al., 
2003; Nozawa et al., 2004a; Grube et 
al., 2006a; Hirano et al., 2006) 
Ezetimibe glucuronide (Oswald et al., 2008) 
Fexofenadine (Nozawa et al., 2004a) 
Fluvastatin (Kopplow et al., 2005; Noe et al., 
2007) 
Glibenclamide (Satoh et al., 2005) 
Latanoprost acid (Kraft et al., 2010) 
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Mesalazine (Konig, 2011) 
Montelukast (Mougey et al., 2009) 
Pravastatin (Nozawa et al., 2004a) 
Pitavastatin (Hirano et al., 2006) 
Pregnenolone sulfate (Grube et al., 2006a) 
Prostaglandin E2 (Tamai et al., 2000) 
Rosuvastatin (Ho et al., 2006) 
Talinolol (Shirasaka et al., 2010) 
Taurocholate (Kobayashi et al., 2003) 
Tebipenem pivoxil (Kato et al., 2010) 
Thyroxine (T4) (Leuthold et al., 2009) 
Unoprostone metabolite (Gao et al., 2005) 
 
 
BDE47: 2,2’,4,4’-Tetrabromodiphenyl ether; BDE99: 2,2’,4,4’,5-pentabromodiphenyl ether; 
BDE153: 2,2’,4,4’,5,5’-hexabromodiphenyl ether 
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Fluo-3, and has little effect on the uptake of estrone-3-sulfate by the same transporter (Gui et al., 
2008). Gemfibrozil inhibits OATP1B1-mediated uptake of pravastatin, fluvastatin, simvastatin 
and taurocholate, but not estrone-3-sulfate or troglitazone sulfate (Noe et al., 2007). 
Rosiglitazone inhibits OATP1B1- and OATP1B3-mediated transport of bromosulfophthalein, 
while stimulating uptake of pravastatin (Bachmakov et al., 2008).  
 
Substrates of the OATPs generally have molecular weights greater than 350 Daltons, and 
as the name suggests are usually anionic, although some OATPs can also transport neutral or 
cationic compounds (Bossuyt et al., 1996). Attempts to define the structural or chemical 
requirements for transport by OATPs have included the development of a pharmacophore model 
based on published apparent affinity (Km values) of substrates (Chang et al., 2005), and a 
CoMFA model based on 25 competitive inhibitors for estradiol-17β-glucuronide (Gui et al., 
2009). The first model suggests that substrates generally contain two hydrogen bond acceptors, 
one hydrogen bond donor, and two hydrophobic regions (Chang et al., 2005). The substrate 
binding site for estradiol-17β-glucuronide may consist of a large hydrophobic region with basic 
residues at both ends (Gui et al., 2009). However, the predicted presence of multiple binding 
sites or translocation pathways complicates the in silica identification of binding sites. 
 
1.3.4: Mechanism of Transport 
 
There are three main classes of mediated transport: passive, primary active, and 
secondary active. Passive transport is driven by the electrochemical gradient of the substrate 
being transported, whereas primary active transport uses the hydrolysis of ATP to directly drive 
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the transport of substrates. Secondary active transport is driven by an electrochemical gradient 
generated by a primary active transporter. It is generally accepted that OATPs operate through 
secondary active transport, but the driving force has not yet been identified. Several studies have 
suggested that OATPs work as electroneutral exchangers, and bicarbonate, glutathione, and 
glutathione conjugates have all been proposed as intracellular compounds that may be exchanged 
for extracellular substrates (Satlin et al., 1997; Li et al., 1998; Franco and Cidlowski, 2006; 
Leuthold et al., 2009). However, there is some evidence that the driving force may vary either by 
transporter or by substrate: for example, intracellular glutathione trans-stimulates uptake of 
multiple substrates by Oatp1a1 (Li et al., 1998), but not by OATP1B1 or OATP1B3 (Mahagita et 
al., 2007). 
 
There is considerable evidence that OATP2B1 has both a broader substrate specificity 
and increased transport ability at acidic pH (Kobayashi et al., 2003; Nozawa et al., 2004a; Sai et 
al., 2006; Varma, 2011). The increased transport can be caused by either increased affinity for 
substrate, or increased turnover rate of the transporter (Nozawa et al., 2004a; Leuthold et al., 
2009). A recent study suggested that this increased substrate affinity was due to the protonation 
of a conserved histidine residue on the extracellular portion of transmembrane domain 3 (TM3) 
(Leuthold et al., 2009). However, this effect seems to be substrate dependent, as numerous 
substrates of OATP2B1 do not show increased transport at reduced pH. OATP2B1 is widely 
expressed throughout the body, including at the apical membrane of enterocytes. The 
phenomenom of increased transport under acidic conditions could result in compounds being 
transported by OATP2B1 into the body, but not being distributed into other OATP2B1-
expressing tissues. For other OATPs, the role of pH is more controversial. A recent study 
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demonstrated that the transport of taurocholate, estradiol-17β-glucuronide, and estrone-3-sulfate 
by OATP1B1 and OATP1B3 is influenced by both pH and membrane potential (Martinez-
Becerra et al., 2011), although a previous report showed no pH effect on estrone-3-sulfate 
transport by OATP1B1 or OATP1B3 (Mahagita et al., 2007). 
 
1.3.5: Structure of OATPs 
 
OATPs are large, membrane-spanning glycoproteins. Several structural features are 
shared by all OATPs. Hydropathy analyses indicate that all OATPs contain 10 or 12 
transmembrane domains, with cytosolic termini. Recently, the 12-transmembrane domain model 
was confirmed for Oatp1a1 (Wang et al., 2008). The OATP “superfamily signature” is a 
consensus sequence found on the c-terminal end of extracellular loop 3, and has been used to 
identify additional family members (Hagenbuch and Meier, 2003). The large extracellular loop 
(ECL5) between transmembrane domains IX and X is conserved in all OATPs/Oatps, and 
contains 10 cysteines that are fully conserved in all human OATPs. In OATP2B1, removing this 
extracellular loop or mutating any of the cysteines into alanine resulted in a protein with limited 
to no surface expression, indicating that disulfide bonds formed by these cysteines may be 
essential for correct protein folding (Hanggi et al., 2006). Both the second and fifth extracellular 
loops (EL2 and EL5) contain multiple potential N-glycosylation sites, some of which have been 
confirmed for individual proteins. Most OATPs also contain a PDZ consensus sequence (Wang 
et al., 2005a) that may be involved in localization to the cell membrane (Kato et al., 2004); (Choi 
et al., 2011). In addition, several of the intracellular loops contain potential 
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phosphorylation sites, which may provide a mechanism for regulation of cell surface expression 
(Choi et al., 2011; Kock et al., 2010). 
 
The large number of transmembrane domains in most mammalian multispecific 
transporters make crystallization extremely difficult. As a result, very few crystal structures exist 
within the major facilitator superfamily. Due to the continuing difficulties associated with 
crystallization of multi-pass transmembrane proteins, other experimental methods are required to 
identify structural components of OATPs that are involved in substrate binding and 
translocation. Three homology models of the putative structure of OATPs have been generated 
(Meier-Abt et al., 2005; Gui and Hagenbuch, 2008; Glaeser et al., 2010). Each model was 
created with comparative modeling, based on the crystal structures of transmembrane 
transporters in the major facilitator superfamily: glycerol-3-phosphate, lactose permease, and 
EmrD, all from E. coli.  
 
Based on one of these homology models, it was proposed that OATPs transport substrates 
through a central positively charged pore via a rocker-switch mechanism (Meier-Abt et al., 
2005). Several positively charged amino acids that are predicted to line the central pore have 
been mutated to other amino acids to test this hypothesis. Amino acids R57, K361 and R580 in 
OATP1B1 (Weaver and Hagenbuch, 2010) and K41, R580 and K361 in OATP1B3 (Glaeser et 
al., 2010; Mandery et al., 2011) were found to be important for full transport activity, suggesting 
that positive charges within the pore are involved in the transport of anionic substrates. Indeed, 
in the case of R57 in OATP1B1 and all three amino acids in OATP1B3, replacing the amino acid 
with another positively charged amino acid restored function of the protein (Glaeser et al., 2010; 
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Weaver and Hagenbuch, 2010; Mandery et al., 2011). For OATP1B1, the mutations also 
produced variant effects on transport, depending on the substrate being tested (Weaver and 
Hagenbuch, 2010). This suggests that estrone-3-sulfate, estradiol-17β-glucuronide, and 
bromosulfophthalein have at least partially distinct binding sites. 
 
Closely related OATPs have distinct substrate specificities, and transport common 
substrates with different kinetic characteristics. Chimeras between OATPs can therefore be used 
to identifiy regions of each protein that are involved in substrate recognition or translocation. 
Several such studies have been conducted using chimeras between OATP1B1 and OATP1B3, 
which share 80% sequence identity. Three neutral amino acids in the tenth transmembrane 
domain (TM10) of OATP1B3 (Y537, S545, and T550) are important for transport of CCK-8, 
which is a substrate of OATP1B3 but not of OATP1B1 (Gui and Hagenbuch, 2008). OATP1B1 
has biphasic saturation kinetics for estrone-3-sulfate transport, with both high-affinity, low-
capacity (Km = 0.1 – 0.6 µM) and low-affinity, high-capacity (Km = 7 – 45 µM) binding sites 
(Tamai et al., 2001; Noe et al., 2007; Gui and Hagenbuch, 2009). TM10 in OATP1B1, 
specifically amino acids L545, F546, L550 and S554, were identified as essential for the high 
affinity portion of estrone-3-sulfate transport (Gui and Hagenbuch, 2009). Similar studies 
showed that transmembrane domains 8 and 9 in OATP1B1 are also critical for estrone-3-sulfate 
transport, and that TM8 but not TM9 contributes to estradiol-17β-glucuronide transport 
(Miyagawa et al., 2009), again suggesting that different binding sites are involved in the 
transport of these two substrates.  
 
Comparative models provide a useful basis for developing hypotheses about the three-
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dimensional structure of a protein, and aid in designing experiments to test proposed mechanisms 
of transport. However, as such models are based on distantly related transporters with low 
sequence similarity and different functions, they are of limited use in practical applications such 
as in silico predictions of substrate specificity or drug-drug interactions. Before the homology 
models can be useful for these applications, they must be improved and key characteristics 
confirmed through experimental procedures. 
 
1.3.6: Polymorphisms 
 
Numerous polymorphisms exist in OATPs, and many have been described in the most 
highly studied OATP family members. OATP1A2 polymorphisms were first described in 2005, 
when Lee et al. identifed 6 nonsynonymous polymorphisms (Lee et al., 2005). Four variants had 
reduced transport activity, two of which showed substrate-dependent effects. Shortly thereafter, 
seven additional nonsynonymous polymorphisms were identified, 4 of which had altered 
transport activity (Badagnani et al., 2006). Two polymorphisms in the promoter region of 
OATP1A2 have been associated with altered clearance of orally-administered imatinib, 
suggesting that OATP1A2 is involved in imatinib absorption and/or distribution (Yamakawa et 
al., 2011). Polymorphisms in OATP2B1 have been less frequently studied, although they have 
been associated with the pharmacokinetics of fexofenadine (Akamine et al., 2010) and 
montelukast (Mougey et al., 2009). 
 
Polymorphisms in OATP1B1 have clearly demonstrated the importance of this 
transporter in the disposition of several drugs. A genome-wide scan of patients with simvastatin-
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induced myopathy identified a strong association with the noncoding single-nucleotide 
polymorphism rs4363657 in OATP1B1 (Link et al., 2008). Altered pharmacokinetics of 
pravastatin and pitavastatin are associated with OATP1B1*1b and OATP1B1*15 
polymorphisms, both of which contain the amino acid substitution N130D (Nishizato et al., 
2003; Mwinyi et al., 2004; Niemi et al., 2004; Chung et al., 2005; Wen and Xiong, 2010). 
Neonates with either of these polymorphisms are at a higher risk for developing severe 
hyperbilirubinemia (Huang et al., 2004; Buyukkale et al., 2011), and the OATP1B1*15 
polymorphism is also associated with higher serum bilirubin levels in adults (Ieiri et al., 2004). 
OATP1B1*5 and OATP1B1*15, which both contain the V174A allele, are associated with 
reduced efficacy of multiple cholesterol-lowering statins (Tachibana-Iimori et al., 2004), with 
increased systemic exposure of the antidiabetic nateglinide (Zhang et al., 2006), and with higher 
system levels of the HIV protease inhibitor lopinavir (Hartkoorn et al., 2010). This allele has not 
been associated with altered pharmacokinetics of rosiglitazone and pioglitazone (Kalliokoski et 
al., 2008), torasemide (Werner et al., 2008), mycophenolic acid (Miura et al., 2007) or 
telmisartan (Miura et al., 2009), indicating either that the amino acid substitution does not alter 
transport of those drugs, or that OATP1B1-mediated transport into hepatocytes does not play a 
significant role in their distribution. 
 
Seven nonsynonymous polymorphisms have been identified in the coding region of 
OATP1B3. Two of these variants, S112A and M233I, were shown to have genotypic frequencies 
of greater than 70% among individuals of European descent, but did not have altered transport of 
six model substrates when compared to the reference sequence (Letschert et al., 2004). A 
separate study performed on an ethnically diverse population revealed lower genotypic 
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frequency of each allele in the African American population than in other ethnic groups and, in 
contrast to the earlier study, found that CCK8 transport activity was significantly reduced in the 
M233I variant compared to the reference sequence (Schwarz et al., 2011). Similar reductions 
were seen in the transport of rosuvastatin. The M233I allele is associated with altered 
pharmacokinetic parameters of the immunosuppressant mycophenolic acid (Miura et al., 2007; 
Picard et al., 2010). Although no associations have been identified between OATP1B3 
geneotype and pharmacokinetics of telmisartan (Miura et al., 2009), or paclitaxel (Smith et al., 
2007), the rs11045585 genotype (IVS12-5676A>G) is associated with higher systemic 
concentrations of docetaxel (Chew et al., 2011) and is also associated with docetaxel-induced 
neutropenia (Kiyotani et al., 2008). 
 
1.4: Interactions with Drug Transporters: Drugs, Foods, and Small 
Molecules 
 
1.4.1: Adverse drug-drug interactions 
 
Adverse drug-drug interactions pose a significant health threat to older Americans, who 
frequently take a large number of medications concurrently. Pharmacokinetic drug-drug 
interactions can take place at any step during drug disposition: absorption, distribution, 
metabolism or excretion. Traditionally, it has been thought that most drug-drug interactions are 
caused by changes in the activity or expression of drug-metabolizing enzymes. However, a 
rapidly growing field of research is demonstrating that these interactions may also be caused by 
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changes in the other three steps of drug disposition, all of which may involve the participation of 
transporters. 
 
The multidrug resistance transporter protein (MDR1, P-glycoprotein, P-gp) has been 
implicated in numerous drug-drug interactions, including those between digoxin and quinidine 
(Fromm et al., 1999), fexofenadine and ketoconazole (Cvetkovic et al., 1999), and paclitaxel and 
valspodar (ten Tije et al., 2003). Uptake transporters may also be involved in drug-drug 
interactions, and may explain the interactions between probenecid and cephalosporin antibiotics 
(Brown, 1993), cerivastatin and cyclosporine (Shitara et al., 2003), rosuvastatin and cyclosporine 
(Simonson et al., 2004), or fexofenadine and grapefruit juice (Bailey et al., 2007; Glaeser et al., 
2007). The latter three interactions are thought to occur at organic anion transporting 
polypeptides. Cerivastatin was withdrawn from the US market due to many deaths from severe 
rhabdomyolysis, which is caused by toxic concentrations of statins in muscles. Many of these 
deaths occurred in patients who were concomitantly taking gemfibrozil (Charatan, 2001), which 
inhibits OATP1B1 transport function, and it has been proposed that inhibition of OATP1B1-
mediated uptake of cerivastatin into liver contributed to its toxicity (Shitara et al., 2004).  
 
To reduce the possibility of such adverse drug-drug interactions, the International 
Transporter Consortium recently suggested that new molecular entities should be tested for 
possible OATP inhibition using a prototypical substrate such as estradiol-17β-glucuronide 
(Giacomini et al., 2010). However, as was discussed in sections 1.3.3 and 1.3.5, there is 
considerable evidence that OATPs have multiple substrate binding sites. Therefore, screening for 
inhibition of a single substrate may be insufficient to identify potential drug-drug interactions 
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1.4.2: Adverse drug-food interactions 
 
Just as drugs can interfere with the disposition of other drugs, so too can food 
components and nutrient supplements. Interactions occurring at drug-metabolizing enzymes, 
such as those caused by grapefruit juice or St. John’s wort, are well known. Recent studies have 
also indicated that these compounds can affect drug uptake and efflux transporters. Such 
interactions can affect the bioavailability of drugs such as fexofenadine and celiprolol, known 
OATP substrates (Greenblatt, 2009). In vitro studies have shown that components of fruit juices, 
teas, and dietary supplements can alter transport mediated by MDR1, MRP2, OATP1A2, 
OATP1B1 and OATP2B1 (Honda et al., 2004; Wang et al., 2005b; Fuchikami et al., 2006; 
Bailey et al., 2007). Although many in vivo studies have shown altered pharmacokinetics of 
drugs when co-administered with these dietary components, it is very difficult to determine 
whether they are caused by altered uptake, efflux, or metabolism. It seems likely that the overall 
effect is a result of all three interactions, and that the ultimate determinant of the 
pharmacokinetic alteration depends on the concentrations of both food and drug, the expression 
levels of proteins, and the identity of the rate-determining step.  
 
1.4.3: Beneficial drug interactions: targeted treatment 
 
Both drug-drug interactions and drug-food interactions are generally unintended, and the 
consequences are adverse to health. However, the principle of altered drug pharamcokinetics 
through concurrent administration of another drug or food can just as easily be beneficial as long 
as the administration is intentional. During World War II, penicillin was frequently administered 
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along with the uricosuric agent probenecid, which drastically reduces the urinary excretion of 
penicillin and thus reduces the required effective dose. By administering the MDR1-inhibiting 
cyclosporine along with paclitaxel or docetaxel, the absorption of taxanes is improved, 
presumably due to reduced efflux from enterocytes (Meerum Terwogt et al., 1998; Malingre et 
al., 2001). Similarly, co-administrating the efflux inhibitor GF120918 with topotecan increased 
the systemic bioavailability of topotecan two-fold (Kruijtzer et al., 2002). Just as inhibiting 
efflux from enterocytes can increase systemic bioavailability, stimulating or inhibiting uptake 
into enterocytes can alter absorption of drugs from the intestine. Selective inhibition of the liver-
specific OATP1B1 or OATP1B3 could also be used to inhibit the first-pass clearance of drugs, 
thereby increasing their systemic bioavailability. Conversely, selective stimulation of OATP1B1 
or OATP1B3 uptake could be used to increase drug delivery to hepatocytes, or to stimulate 
OATP1B3-mediated anticancer drug uptake into OATP1B3-expressing cancer cells. 
 
1.5: Specific Aims of this Dissertation 
 
Adverse drug-drug interactions are a common result of comorbidity and polypharmacy, 
and pose a significant health threat to older Americans. Such interactions occurring at drug- 
metabolizing enzymes are well studied and characterized; however, recent research has shown 
that these interactions may also be caused by alterations in transporter activity. Organic anion 
transporting polypeptides (OATPs) are transporters that mediate the uptake of a broad range of 
drugs and other xenobiotics into cells. Among the drugs transported by OATPs are numerous 
statins and antidiabetic agents, the pharmacokinetics of which depend upon OATP-mediated 
uptake into hepatocytes. Drug-drug interactions at OATPs can alter the pharmacokinetic profiles 
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of these or other substrates, leading to decreased efficacy or increased toxicity. Due to the 
limited structural information available for OATPs, little is known about the mechanism of 
substrate binding and translocation. Subsequently, little is known about the mechanism of drug- 
drug interactions that occur at OATPs. Without a detailed understanding of these mechanisms, it 
will remain impossible to predict potentially hazardous OATP-mediated drug-drug interactions. 
 
The studies presented in this dissertation were designed to address the lack of 
understanding of the mechanism through which drug-drug interactions occur. In order to 
decrease the frequency of OATP-mediated drug-drug interactions by improving pre-clinical 
screening methods, the objective of this dissertation is to characterize the mechanism of drug-
drug interactions at OATP1B1 and OATP1B3. By testing the central hypothesis that OATP1B1 
and OATP1B3 have overlapping but distinct binding sites, which are affected in substrate-
dependent ways, I have discovered novel information about the mechanism of drug-drug 
interactions occurring at OATPs. A more detailed understanding of this mechanism will allow 
more accurate prediction and prevention of such occurrences. 
 
Recent studies suggest that these liver-specific OATPs contain multiple substrate binding 
sites. Experiments in our laboratory demonstrate that mutations in OATPs have varied effects on 
the transport of different substrates. Furthermore, our laboratory has demonstrated that 
clotrimazole can stimulate, inhibit, or have no effect on OATP1B3 function, depending upon the 
substrate transported. Based on these observations, I generated the central hypothesis of this 
dissertation: OATP1B1 and OATP1B3 have overlapping but distinct binding sites, which  
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are affected in substrate-dependent ways. This hypothesis was tested via the following 
specific aims: 
 
1.5.1: Specific Aim 1: Identify and characterize substrate-dependent effects of plant 
compounds on OATP-mediated transport.  
 
Our working hypothesis was that plants are a rich source of compounds that have 
substrate-dependent interactions with OATPs. Interacting compounds were identified by 
screening a library of plant compounds for inhibition or stimulation of OATP-mediated uptake of 
two model substrates. Substrate-dependent interactions were further studied with additional 
model substrates and characterized by determining potency (IC50 or EC50). Completion of this 
specific aim identified two plants that contained OATP-modifying compounds, and provides a 
basis for identifying stimulators of OATP1B3-mediated transport. 
 
1.5.1a: Interaction of green tea catechins with organic anion transporting polypeptides. 
To determine whether green tea catechins were a potential cause of drug-food interactions 
occurring at OATP transporters, uptake of the model substrate estrone-3-sulfate by cells 
expressing OATP1A2, OATP1B1, OATP1B3, or OATP2B1 was quantified in the absence 
and presence of the four most abundant flavonols found in green tea. In addition, uptake of 
green tea catechins by the four OATPs was quantified and characterized. 
 
1.5.1b: Isolation of modulators of organic anion transporting polypeptides 1B1 and 1B3 
from Rollinia emarginata Schlecht (Annonaceae). In this study, a bioassay guided isolation 
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approach was used to identify specific modulators of OATP1B1 and OATP1B3 from the 
organic extract of Rollinia emarginata Schlecht (Annonaceae). Fractions of the plant extract 
were screened for effects on OATP1B-mediated transport of the model substrates estradiol-
17β-glucuronide and estrone-3-sulfate. 
 
1.5.2. Identify regions of OATP1B3 involved in the binding and/or translocation of 
individual model substrates.  
 
Our working hypothesis was that the mechanism of substrate-specific drug-drug 
interactions is dependent on the presence of multiple binding sites. As the first step toward 
characterization of this mechanism, cysteine-substituted OATP1B3 mutants were produced and 
tested to identify regions that are involved in substrate recognition and translocation.  
	  
	  
	  41	  
Chapter 2 
Experimental Materials and Methods 
 
2.1: Materials 
 
[3H]Estrone-3-sulfate and [3H]estradiol-17β-glucuronide were purchased from 
PerkinElmer Life and Analytical Sciences (Waltham, MA). [3H]Epigallocatechin gallate (10 
Ci/mmol) was purchased from American Radiolabeled Chemicals (St. Louis. MO). Unlabeled 
estrone-3-sulfate, estradiol-17β-glucuronide, (−)-epicatechin, (−)-epigallocatechin, (−)-
epicatechin gallate, and (−)-epigallocatechin gallate and rifampicin were purchased from Sigma-
Aldrich (St. Louis, MO). Fluo-3, pentapotassium salt was purchased from Invitrogen (Carlsbad, 
CA). Green tea (Camellia sinensis) biomass was provided by the Royal Estates Tea Company, a 
Division of Thomas J. Lipton, Co. (Englewood Cliffs, NJ). Above-ground plant material of 
Rollina emarginata was collected and identified in February 1999 in Argentina by R. Fortunato 
& A. Cabral (INTA) collection # ARP 613. LAT: 25°14'0''5 South LON:57°57'0''0 West. RN 86, 
2Km NE of Patino, Department Primavera, Province Formosa. 
 
Human embryonic kidney (HEK-293) cells, Eagle's minimum essential medium, and 
Dulbecco's modified Eagle's medium (high glucose) were from American Type Culture 
Collection (Manassas, VA). Dulbecco's modified Eagle's medium (low glucose) was purchased 
from Caisson Laboratories (North Logan, UT). Fetal bovine serum was obtained from HyClone 
(Logan, UT). Sulfo-NHS-SS-biotin, NeutrAvidin agarose beads and BCA protein assay kits were 
from Thermo Fisher Scientific (Rockford, IL). Maleimide-PEG2-biotin was purchased from 
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Invitrogen (Carlsbad, CA), and sodium (2-sulfonatoethyl)methanethiosulfonate (MTSES) was 
purchased from Toronto Research Chemicals (North York, Ontario). All other materials were 
purchased from Sigma-Aldrich or Invitrogen.  
 
2.2: Plant Compound Extraction and Isolation. 
 
Plant compound extraction and isolation was performed by Gemma O’Donnell, Ph.D. 
(green tea extraction) or by Juan J. Araya (Rollinia emarginata extraction and isolation) under 
the supervision of Barbara N. Timmermann, Ph.D., in the Department of Medicinal Chemistry at 
the University of Kansas, Lawrence, Kansas, according to the following protocols. 
 
Green Tea Extraction. A sample of green tea biomass was extracted exhaustively with 
10 ml of H2O (70°C, 10 min). The extract was concentrated in vacuo and dried overnight at 30°C 
in a vacuum oven. Rollinia emarginata Extraction and Isolation. The extraction and isolation 
protocol is outlined in the separation diagram shown in Figure 4-1. Dried and ground plant 
material (562 g) was extracted with methanol (MeOH) and dichloromethane (CH2Cl2) mixture 
(1:1, v/v) three times for 24 h. periods at room temperature. Organic solvents were removed in 
vacuo at 35°C; the residue was suspended in MeOH:H2O (9:1, v/v) and partitioned with hexanes 
(HEX fraction). After removal of MeOH, the aqueous layer was extracted successively with 
CH2Cl2 (DCM fraction) and butanol (BUOH fraction). The HEX fraction was then subjected to 
silica gel column chromatography (Si-Gel CC) (32-64 µm, 36x460 mm) and eluted with a 
gradient of hexane-ethyl acetate (EtOAc) (20:1 to 0:100, v/v) to afford 20 subfractions (A to T), 
which were combined according to TLC analysis. Subfraction HEX-G (310 mg) was submitted 
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to Si-Gel CC (12-26 µm, 36×230 mm) using a gradient of hexane and acetone (15:1 to 5:1, v/v) 
to obtain three subfractions (G1-G3). Subfraction HEX-G1 (205 mg) was purified using Si-Gel 
CC (CH2Cl2:EtOAc, 20:1, v/v) to afford Compound 3 (120 mg). Subfraction HEX-G2 was 
purified with Si-Gel CC (12-16 µm, 20×460 mm) using hexane, CH2Cl2 and methyl tert-butyl 
ether (20:15:1, v/v/v) as mobile phase to yield Compound 4 (10.4 mg). Also, subfraction HEX-N 
(284 mg) was separated using Si-gel CC (32-64µm, 36×230 mm) and CH2Cl2-EtOAc (10:1, v/v) 
as a solvent system to yield a mixture of Compounds 1 and 2 (103 mg), which was resolved by 
means of semi preparative HPLC (reverse phase C-18, 10×250 mm, 5µm, solvent A: acetonitrile, 
solvent B :water, gradient: 80%A to 100%A in 45 min). Fraction BUOH (19.7 g) was subject to 
MCI-Gel CHP20P CC (65×350 mm) and eluted with various mixtures of water and MeOH 
(100:0, 25:75, 50:50,75:25, 0:100; v/v) to afford four fractions (A-D). Subfraction BUOH-B 
(2.2g) was submitted to Sephadex LH-20 with MeOH as a mobile phase and a total of 180 
fractions (7.5 mL each) were collected and combined into nine fractions (1-9) after TLC 
analysis. Pigments present in fraction BUOH-B7 (530 mg) were removed with a small Si-gel 
plug using CH2Cl2:MeOH:H2O (4:1:0.1, v/v/v) as eluent to obtain a mixture of Compounds 5 
and 6 (450 mg). A portion of this mixture (40 mg) was purified using semi-preparative HPLC 
(reverse phase C-18, 10×250 mm, 5µm, solvent A: acetonitrile, solvent B: water, isocratic 
18%A) to obtain Compounds 5 (24 mg) and 6 (6.2 mg). 
 
2.3: Plant Compound Identification 
 
Plant compound identification was performed by Juan J. Araya under the supervision of 
Barbara N. Timmermann, Ph.D., in the Department of Medicinal Chemistry, at the University of 
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Kansas, Lawrence, Kansas. The structures of compounds isolated from Rollinia emarginata were 
established by one and two dimension NMR experiments and compared with those in the 
literature (Seebacher et al., 2003; Zhang et al., 2005; Muzitano et al., 2006; Faini et al., 2007). 
IR, UV, and HRMS were also in agreement with the proposed structures. NMR experiments 
were performed in a Bruker AVIII 500 instrument with a dual C/H cryoprobe. Standard 1H-
NMR, 13C-NMR, COSY, HSQC and HMBC experiments were recorded of each of the pure 
compounds. An Agilent 1200 system with a 6300 Series Ion Trap detector was used for LCMS 
experiments. An Agilent RP-C18 (15x4.1mm, 5µm) column was used and different gradients of 
acetonitrile and water were applied as the mobile phase depending on polarity of samples. 
HRMS was obtained with a LCT Premier instrument (Waters Corp., Milford, MA). The purity of 
each compound was determined to be over 95% by HPLC analysis. 
 
2.4: Site-directed Mutagenesis 
 
 The backbone for all OATP1B3 mutagenesis experiments is the previously described 
His-tagged OATP1B3 in the pcDNA5/FRT expression vector (Gui and Hagenbuch, 2008). Site-
directed mutagenesis was performed with primers custom synthesized by Invitrogen, using the 
Quikchange II Site-Directed Mutagenesis Kit from Agilent Technologies (Santa Clara, CA), as 
per the manufacturer’s instructions. Cysteine-substituted constructs were fully sequenced on both 
strands. Mutant Q54C could not be propagated in XL1-Blue Supercompetent cells (Agilent 
Technologies) or in One Shot® TOP10 Chemically Competent E. coli (Invitrogen), and is not 
included in the analysis. 
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2.5: Cell Culture 
 
CHO cells stably transfected with human OATP1B1, OATP1B3, and OATP2B1 were 
generated in our laboratory previously and were cultured as described previously (Gui et al., 
2008; Pacyniak et al., 2010). HeLa cells were grown in Eagle's minimum essential medium 
supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. 
HEK-293 cells were grown in Dulbecco's modified Eagle's medium containing 4.5 g/l D-
glucose, 2 mM L-glutamine, 25 mM HEPES, and 110 mg/l sodium pyruvate, supplemented with 
10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. All cells were 
maintained in a humidified environment at 37°C and 5% CO2. 
 
2.6: OATP Expression 
 
CHO cells stably expressing OATP1B1 or OATP1B3 and wild-type CHO cells were 
seeded on 24- or 96-well plates and grown for 48-72 hours. Once cells had reached visual 
confluency, gene expression was non-specifically induced in the absence of geneticin by 
exchanging medium for that containing 5 mM sodium butyrate (Palermo et al., 1991). 
Experiments were performed 24 h after induction. CHO cells stably expressing OATP2B1 or the 
empty vector were seeded on 24-well plates 48 h before uptake experiments; OATP2B1 
expression in this cell line did not require sodium butyrate induction. OATP1A2 was transiently 
expressed in HeLa or HEK-293 cells. HeLa cells were seeded on 12-well plates and transfected 
using the vaccinia virus T7 system, essentially as described previously (Lee et al., 2005). 
Between 16 and 20 h before uptake experiments, cells were infected with vaccinia virus in 
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serum-free Opti-MEM medium and incubated for 1 h at 37°C. After washing, cells were 
transfected with pcDNA5/FRT containing the open reading frame of a His-tagged OATP1A2 or 
with the empty vector using Lipofectamine 2000, as per the manufacturer's instructions. HEK-
293 cells were seeded on 24-well plates pretreated with poly-D-lysine and were transfected with 
pExpress-1 (Express Genomics, Inc., Frederick, MD) containing OATP1A2 or with the empty 
vector approximately 48 h before uptake experiments. OATP1B3 mutant constructs were also 
transiently expressed in HEK-293 cells. Cells were seeded in 12- or 24-well tissue culture plates 
pre-treated with poly-D-lysine. At approximately 90% visual confluence, cells were transfected 
with wild-type or mutant OATP1B3 constructs or the empty plasmid using FuGENE-HD 
transfection reagent from Roche (Basel, Switzerland), following the manufacturer’s instructions. 
All experiments were performed forty-eight hours after transfection. 
 
2.7: Transport Assays 
 
Uptake experiments were performed essentially as described previously for CHO (Gui et 
al., 2008) and HEK-293 cells (Weaver and Hagenbuch, 2010). CHO uptake buffer contained 100 
mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2 and 10 mM HEPES; pH was adjusted to 7.4 
using Trizma base. HeLa uptake buffer contained 100 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 
mM MgCl2 and 10 mM Hepes and was adjusted to pH 7.5 with Trizma base. For experiments 
involving OATP1A2, HEK-293 uptake buffer contained 142 mM NaCl, 5 mM KCl, 1 mM 
KH2PO4, 1.2 mM MgSO4, 1.5 mM CaCl2, 5 mM glucose, and 12.5 mM HEPES, and was 
adjusted to pH 7.4 with Trizma base. For experiments with OATP1B3 transiently expressed in 
HEK-293 cells, CHO uptake buffer was used. 
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Cells were washed three times with prewarmed (37°C) uptake buffer, then cells were 
incubated at 37°C with uptake buffer containing substrate for a given timepoint. Uptake was 
terminated by quickly removing the uptake solution and washing four times with ice-cold uptake 
buffer. To quantify uptake of radiolabeled substrates, cells were lysed with 1% Triton X-100 in 
phosphate-buffered saline, and the radioactivity was quantified with liquid scintillation counting. 
To measure uptake of Fluo-3, cells were lysed with 1% Triton X-100 in phosphate-buffered 
saline containing 1 mM CaCl2, and fluorescence was quantified on a Synergy HT microplate 
reader (BioTek Instruments, Winooski, VT) at an excitation wavelength of 485 nm and an 
emission wavelength of 528 nm. Unlabeled catechins were detected using a Quattro Premier 
high-performance liquid chromatography tandem mass spectrometer (Waters, Milford, MA) in 
electrospray negative ion mode using a C18 column (50 × 2.1 mm, 5 µm; Phenomenex, 
Torrance, CA) at 40°C. The mobile phase consisted of 60:40 acetonitrile and 1% acetic acid, and 
was eluted isocratically with a flow rate of 0.3 ml/min. Cells were lysed in mobile phase 
containing 1 µM ethyl gallate, and lysate was centrifuged at 20,000 xg for 20 min to remove 
protein before injection. The transitions monitored were 441.15 > 169.1 for ECG, 457.05 > 169.1 
for EGCG, and 197.17 > 124.2 for ethyl gallate (internal standard). QuanLynx software (Waters) 
was used to quantify mass spectrometry data. Protein concentrations were determined with BCA 
assay kits (Thermo Fisher Scientific, Waltham, MA), and uptake was corrected for protein. Net 
OATP-mediated uptake was defined as the uptake by OATP-expressing cells minus the uptake 
by the appropriate control cell line (wild-type CHO cells for OATP1B1 and OATP1B3, CHO 
cells stably expressing empty vector for OATP2B1, and HeLa or HEK-293 cells transiently 
expressing the empty vector for transiently expressed OATP1A2 and OATP1B3).  
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2.8: Cell Surface Biotinylation and Immunoblot Analysis 
 
Cell surface expression was quantified by incubating cells with 1 mg/ml sulfo-NHS-SS-
biotin in PBS for 1 h. at 4°C. After quenching the reaction with 100 mM glycine in PBS, cells 
were lysed for 10 min. on ice, in buffer containing 10 mM Tris (pH 7.5), 150 mM NaCl, 1 mM 
EDTA, 0.1% SDS, 1% Triton X-100 and protease inhibitors (Roche). Lysate was centrifuged at 
10,000 xg for 2 min. Supernatant was added to neutravadin agarose beads, and incubated for 1 h. 
at room temperature. Beads were washed three times for 5 min. with lysis buffer, then 
biotinylated proteins were eluted by incubating in 2x Laemmli buffer containing 5% 2-
mercaptoethanol for 30 min. Protein was run on a 7.5% SDS-PAGE gel and transferred to 
nitrocellulose membrane. Western blots were probed with a monoclonal tetra-His antibody from 
Qiagen (Valencia, CA), following the manufacturer’s recommendations. The plasma membrane 
marker Na+/K+ ATPase was detected as a control for biotinylation. 
 
2.9: Methanethiosulfonate and Maleimide Accessibility Reactions 
 
HEK293 cells transiently expressing OATP1B3 were washed three times with 
prewarmed (37°C) uptake buffer, then incubated with uptake buffer containing 10 mM MTSES 
for ten min. at 37°C. Cells were then washed two times with prewarmed uptake buffer before 
performing uptake experiments as described above. Uptake was normalized for protein 
concentration, and uptake by cells transfected with the empty vector was subtracted from each 
uptake value. 
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 To determine accessibility of inserted cysteines to the aqueous extracellular 
environment, cells transiently expressing wild-type or mutant OATP1B3 were incubated with the 
membrane impermeable, thiol-specific reagent maleimide-PEG2-biotin (0.5 mg/ml in PBS, pH 
7.0) for one h. at 4°C. After thorough washing, cells were lysed and affinity purified with 
neutravidin-agarose beads as described above. Biotinylated proteins were eluted by boiling in 2x 
Laemmli sample buffer containing 5% 2-Mercaptoethanol for five min. Both eluted proteins and 
total cleared lysate (as a control for transfection) were run on 7.5% SDS-PAGE gels and 
transferred to nitrocellulose membranes. Western blots were probed with a monoclonal tetra-His 
antibody from Qiagen (Valencia, CA), following the manufacturer’s recommendations.  
 
2.10: Calculations and Statistics 
 
All calculations were performed using Prism 5 (GraphPad Software Inc., San Diego, 
CA). IC50 values and kinetic parameters were determined within the initial linear period of 
uptake after correction for protein and subtraction of uptake by the control cell line. Statistical 
analyses were performed with two-way analysis of variance followed by the Bonferroni post-
test, or with two-tailed paired t-tests. 
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Chapter 3 
Interactions of Green Tea Catechins with Organic Anion-Transporting 
Polypeptides 
 
3.1: Abstract 
 
Organic anion-transporting polypeptides (OATPs) are multispecific transporters that 
mediate the uptake of numerous drugs and xenobiotics into cells. Here, we examined the effect 
of green tea (Camellia sinensis) catechins on the function of the four OATPs expressed in human 
enterocytes and hepatocytes. Uptake of the model substrate estrone-3-sulfate by cells expressing 
OATP1A2, OATP1B1, OATP1B3, or OATP2B1 was measured in the absence and presence of 
the four most abundant flavonols found in green tea. Uptake by OATP1A2, OATP1B1, and 
OATP2B1 was inhibited by epicatechin gallate (ECG) and epigallocatechin gallate (EGCG) in a 
concentration-dependent way. In contrast, OATP1B3-mediated uptake of estrone-3-sulfate was 
strongly stimulated by EGCG at low substrate concentrations. The effect of EGCG on OATP1B3 
was also studied with additional substrates: uptake of estradiol-17β-glucuronide was unchanged, 
whereas uptake of Fluo-3 was noncompetitively inhibited. Both ECG and EGCG were found to 
be substrates of OATP1A2 (Km values of 10.4 and 18.8 µM, respectively) and OATP1B3 (34.1 
and 13.2 µM, respectively) but not of OATP1B1 or OATP2B1. These results indicate that two of  
 
______________________________________________________________________________ 
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the major flavonols found in green tea have a substantial effect on the function of OATPs 
expressed in enterocytes and hepatocytes and can potentially alter the pharmacokinetics of drugs 
and other OATP substrates. In addition, the diverse effects of EGCG on the transport of other 
OATP1B3 substrates suggest that different transport/binding sites are involved.  
 
3.2: Introduction 
 
Adverse drug-drug interactions are a common result of comorbidity and polypharmacy 
and pose a significant health threat. Furthermore, dietary supplements are increasingly popular, 
and some of their ingredients have the potential for additional drug interactions. These adverse 
drug interactions may be caused by alterations in efflux (Durr et al., 2000) and uptake 
transporters (Fattinger et al., 2000), such as the organic anion-transporting polypeptides 
(OATPs). OATPs are multispecific transporters that mediate the cellular uptake of a wide range 
of amphipathic compounds, including numerous drugs (Hagenbuch and Gui, 2008). Four well 
characterized OATPs, OATP1A2, OATP1B1, OATP1B3 and OATP2B1, are expressed in the 
small intestine and the liver, where the likelihood of drug-drug or drug-food interactions is the 
greatest.  
 
Both OATP1A2 and OATP2B1 are expressed at the apical membrane of enterocytes 
(Kobayashi et al., 2003; Glaeser et al., 2007) where they can contribute to the absorption of 
drugs such as statins, sartans, fexofenadine, talinolol, and methotrexate (Shimizu et al., 2005; 
Badagnani et al., 2006; Ho et al., 2006; Kitamura et al., 2008; Shirasaka et al., 2010). In the liver, 
OATP1B1, OATP1B3, and OATP2B1 are expressed at the basolateral membrane of hepatocytes 
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(Abe et al., 1999; Konig et al., 2000b; Kullak-Ublick et al., 2001). Here, these proteins are 
involved in the removal of drugs from the bloodstream into hepatocytes. With their broader 
substrate specificity, OATP1B1 and OATP1B3 are thought to play a more important role in 
hepatocellular drug uptake than OATP2B1 (Smith et al., 2005b; Hagenbuch and Gui, 2008; 
Kindla et al., 2009).  
 
The importance of OATPs to drug disposition has been highlighted by pharmacokinetic 
studies that correlated changes in the bioavailability of drugs with polymorphisms of OATPs 
(Kalliokoski and Niemi, 2009). Thus, inhibition or stimulation of OATP function by food or 
dietary supplements can alter the pharmacokinetics of OATP substrates and potentially lead to 
adverse effects. Recent studies have indicated that flavonoids found in fruit juices, in green tea, 
and in many dietary supplements can alter the function of OATP1A2, OATP1B1, and OATP2B1 
(Wang et al., 2005b; Fuchikami et al., 2006; Bailey et al., 2007). Such interactions can affect the 
bioavailability of drugs such as fexofenadine and celiprolol, known OATP substrates 
(Greenblatt, 2009).  
 
Green tea is a commonly consumed beverage and has received much attention for its 
reputed health benefits. Several epidemiological studies have shown a reduced risk of 
gastrointestinal cancers among those who regularly consume green tea (Liu et al., 2008). 
Compared with other tea preparations, green tea is characterized by very high concentrations of 
catechins, which make up 30 to 40% of its dry weight. The catechins include epicatechin (EC), 
epigallocatechin (EGC), epicatechin gallate (ECG), and epigallocatechin gallate (EGCG). 
EGCG, the most predominant catechin in green tea, has been highly studied for its in vitro 
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effects. Because of the many apparent health benefits of green tea and EGCG, green tea 
beverages and extract supplements are widely used, creating an increased risk of adverse 
interactions. EGC and EGCG have been shown to inhibit OATP1B1-mediated uptake of 
dehydroepiandrosterone sulfate (Wang et al., 2005b), whereas all four catechins inhibited 
estrone-3-sulfate uptake mediated by OATP2B1 (Fuchikami et al., 2006). However, the effect of 
catechins on the function of OATP1A2 and OATP1B3 has not been reported, and it is not known 
whether any of these four catechins are transported by any of the OATPs. Therefore, in the 
present study we asked the question whether all four major catechins inhibit OATP-mediated 
uptake and whether they are transported by OATPs.  
 
3.3: Results 
 
3.3.1 Characterization of OATP1A2 and OATP2B1 Expression Systems. 
 
OATP2B1 was expressed at high levels on the plasma membrane of the stably transfected 
OATP2B1-expressing CHO cells as confirmed using an anti-His antibody (data not shown). To 
minimally characterize OATP2B1 and the transiently expressed OATP1A2 at a functional level, 
we used the model substrate estrone-3-sulfate. Uptake of 100 µM estrone-3-sulfate was linear for 
at least 30 s for both OATP1A2 and OATP2B1 (data not shown); therefore, subsequent 
experiments were performed at 30 s for OATP1A2 and 20 s for OATP2B1. In both systems, 
transport of estrone-3-sulfate was saturable, with apparent Km and Vmax values of 16.1 ± 0.2 µM 
and 640 ± 150 pmol/mg · min for OATP1A2 and 14.8 ± 4.0 µM and 2.54 ± 0.57 nmol/mg · min 
for OATP2B1, respectively.  
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3.3.2: Effect of Green Tea Extract and Catechins on OATP-Mediated Uptake of Estrone-
3-Sulfate. 
 
To determine the effects of green tea components on OATP function, we measured 
OATP-mediated uptake of 0.1 µM estrone-3-sulfate in the presence of 0.03 µg/ml green tea 
extract or 100 µM green tea catechin under initial linear rate conditions. EC and EGC did not 
significantly affect estrone-3-sulfate uptake by any of the four cell lines (Figure 3-1, A–D). ECG 
and EGCG inhibited uptake of estrone-3-sulfate by OATP1A2, OATP1B1, and OATP2B1. Of 
interest, OATP1B3-mediated uptake of estrone-3-sulfate was unaffected by ECG but strongly 
stimulated by EGCG (Figure 3-1C). To further characterize the effect of the gallated catechins 
on OATP-mediated uptake of estrone-3-sulfate, we determined uptake of 0.1 µM estrone-3-
sulfate in the presence of increasing concentrations of ECG or EGCG. As shown in Figure 2, 
both ECG and EGCG exhibited a concentration-dependent inhibition of estrone-3-sulfate uptake 
mediated by OATP1A2, OATP1B1, and OATP2B1 (Figure 3-2, A, B, and D). Uptake by 
OATP1A2 and OATP2B1 was more strongly inhibited by ECG (IC50 values of 10.2 and 35.9 
µM, respectively) than by EGCG (54.8 and 101 µM, respectively), whereas uptake by OATP1B1 
was more strongly inhibited by EGCG than by ECG (IC50 values of 7.8 and 58.6 µM, 
respectively). EGCG stimulated estrone-3-sulfate uptake by OATP1B3 5-fold at concentrations 
of 30 to 300 µM. The stimulatory effect remained at 1 mM EGCG; however, it was greatly 
reduced (Figure 3-2C). 
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Figure 3-1:  
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Figure 3-1:  
 
Effect of green tea extract and catechins on OATP-mediated estrone-3-sulfate uptake. Cells 
were coincubated with 0.1 µM [3H]estrone-3-sulfate (E3S) and 0.03 µg/ml green tea extract, 100 
µM EC, EGC, ECG, EGCG, or the vehicle control (1% DMSO) at 37°C for 20 s [OATP1B1 (B), 
OATP1B3 (C), and OATP2B1 (D)] or 30 s [OATP1A2 (A)]. After correction for protein, uptake 
into empty vector (OATP1A2 and OATP2B1) or wild-type control cells (OATP1B1 and 
OATP1B3) was subtracted to determine OATP-mediated uptake. Values are expressed as a 
percentage of vehicle control; each value is the mean ± S.E.M. of three independent experiments. 
Asterisks represent statistically significant differences from the DMSO control (**, p < 0.005; 
***, p < 0.001).  
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Figure 3-2:  
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Figure 3-2:  
 
Concentration-dependent effects of green tea catechins on OATP-mediated estrone-3-
sulfate uptake. Cells were coincubated with 0.1 µM [3H]estrone-3-sulfate (E3S) and increasing 
concentrations of ECG or EGCG at 37°C as described in the legend to Figure 3-1. A, OATP1A2. 
B, OATP1B1. C, OATP1B3. D, OATP2B1. Values are expressed as a percentage of vehicle 
control; each value represents the mean ± S.E.M. of three independent experiments. 
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3.3.3: Substrate-Dependent Effect of ECG and EGCG on OATP1B3-Mediated Uptake. 
 
On the basis of previous evidence for substrate-dependent stimulation of OATP1B3 (Gui 
et al., 2008), we measured the effects of increasing concentrations of ECG and EGCG on the 
uptake of two additional model substrates of OATP1B3, estradiol-17β-glucuronide (0.1 µM) and 
Fluo-3 (1 µM), as well as estrone-3-sulfate (0.1 µM). As can be seen in Figure 3-3A, ECG 
inhibited uptake of estradiol-17β-glucuronide with an IC50 value of 130 µM, slightly inhibited 
estrone-3-sulfate uptake at concentrations higher than 100 µM, and strongly inhibited uptake of 
Fluo-3 (IC50 = 6.9 µM). EGCG had no effect on the uptake of estradiol-17β-glucuronide; 
however, it strongly inhibited uptake of Fluo-3 with an IC50 value of 8.4 µM, whereas it 
stimulated estrone-3-sulfate uptake with an EC50 value of 10.5 µM (Figure 3-3B).  
 
To investigate the mechanism of this substrate dependence, we determined the effect that 
ECG and EGCG had on the kinetic parameters of each affected OATP1B3 substrate (Figure 3-
4). Both ECG and EGCG noncompetitively inhibited OATP1B3-mediated uptake of Fluo-3, 
reducing the Vmax from 9.8 ± 0.6 to 4.3 ± 0.8 and 5.6 ± 0.6 pmol/mg · min, respectively, whereas 
they had no effect on the Km (2.5 ± 0.8, 2.1 ± 1.8, and 2.7 ± 1.4 µM) (Figure 3-4, A and B). ECG 
also demonstrated noncompetitive inhibition of estradiol-17β-glucuronide uptake, decreasing the 
Vmax from 240 ± 40 to 110 ± 40 pmol/mg · min, while not affecting Km (19 ± 3 to 17 ± 5 µM) 
(Figure 4C). Surprisingly, EGCG also significantly decreased the maximal rate of estrone-3-
sulfate transport, reducing the Vmax from 2.1 ± 0.1 to 0.36 ± 0.03 nmol/mg · min (Fig.	  3-­‐4D). 
However, the Km was also strongly decreased, from 95 ± 9 to 12 ± 5 µM. This 5- to 10-fold  
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 Figure 3-3:  
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Figure 3-3: 
 
Substrate-dependent effects of ECG and EGCG on OATP1B3-mediated transport. 
OATP1B3-expressing and wild-type CHO cells were coincubated with 0.1 µM [3H]estrone-3-
sulfate (E3S, ●), 0.1 µM [3H]estradiol-17β-glucuronide (E17β, ■), or 1 µM Fluo-3 (▴) and 
increasing concentrations of ECG (A) or EGCG (B) at 37°C as described in the legend to Figure 
3-1. Values are expressed as a percentage of vehicle control; each value represents the mean ± 
S.E.M. of three independent experiments. 
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Figure 3-4: 
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Figure 3-4: 
 
Effect of ECG and EGCG on the kinetics of OATP1B3-mediated transport. OATP1B3-
expressing and wild-type CHO cells were coincubated with the stated concentrations of ECG or 
EGCG (■) or the vehicle control (1% DMSO, ●) and increasing concentrations of Fluo-3 (A and 
B), estradiol-17β-glucuronide (E17β) (C), or estrone-3-sulfate (E3S) (D). A–C are representative 
graphs from at least three independent experiments. Each value shown in D represents the mean 
± S.E.M. of at least three independent experiments. 
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increase in affinity results in the stimulation of estrone-3-sulfate transport observed at the low 
(0.1 µM) concentrations used in the initial inhibition experiments.  
 
3.3.4: OATP-Mediated Uptake of ECG and EGCG. 
 
Given that inhibitors of transport are sometimes also substrates, we tested whether either 
ECG or EGCG was transported by these four OATPs. We measured accumulation of 100 µM 
ECG or EGCG in the OATP-expressing or control cells after a 10-min incubation. As 
summarized in Figure 3-5, both OATP1A2 and OATP1B3 transported ECG and EGCG. 
Although ECG and EGCG were clear inhibitors of OATP1B1 and OATP2B1, we did not detect 
significant uptake by either OATP. Uptake of both catechins by OATP1A2 and OATP1B3 
increased with time and was linear for at least 2 to 5 min (data not shown). Uptake was saturable, 
with apparent Km values between 10 and 34 µM (Figure 3-6). OATP1A2 transports EGCG with a 
maximal rate of transport (Vmax) almost twice that of ECG (100 and 60 pmol/mg*min, 
respectively), whereas OATP1B3 has a Vmax approximately 6 times higher for ECG than for 
EGCG (2.2 and 0.340 nmol/mg*min, respectively).  
	  
	  
	  65	  
Figure 3-5: 
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Figure 3-5: 
 
Uptake of green tea catechins by OATPs. Cells were incubated with 100 µM ECG or EGCG at 
37°C for 10 min. Uptake by each OATP-expressing cell line was divided by the uptake by its 
appropriate control cell and is expressed as fold uptake over control. Each value represents the 
mean ± S.D. of at least two experiments performed in triplicate. Asterisks represent statistically 
significant uptake compared with control cell lines (*, p < 0.05; **, p < 0.005; ***, p < 0.001). 
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Figure 3-6: 
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Figure 3-6:  
 
Kinetics of epicatechin gallate and epigallocatechin gallate uptake mediated by OATP1A2 
or OATP1B3. Uptake of increasing concentrations of ECG (A and B) or [3H]EGCG (C and D) 
was measured at 37°C under the initial linear rate conditions. After subtraction of the values 
obtained with control cells, net OATP1A2-mediated (A and C) or OATP1B3-mediated (B and 
D) uptake was fitted to the Michaelis-Menten equation to determine Km and Vmax values. A and 
B, plot of mean data points from at least three independent experiments. C and D, representative 
graphs with mean ± S.E.M. of three independently determined Km values. 
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3.4: Discussion 
 
The present study addressed the question of whether the four major green tea catechins 
affect the activity of all OATPs expressed in the small intestine and liver. In addition, we 
investigated whether the catechins that do alter OATP activity are transported by OATPs. Our 
results demonstrate that although EC and EGC have minimal effect on OATPs, ECG and EGCG 
significantly alter the function of all four OATPs investigated. We found that the effects of ECG 
and EGCG on OATP1B3-mediated transport were substrate-dependent and could cause 
noncompetitive inhibition or stimulation of activity. In addition, we showed that both ECG and 
EGCG are substrates of OATP1A2 and OATP1B3 but are not transported by OATP1B1 or 
OATP2B1, despite the strong inhibition of estrone-3-sulfate transport by these two proteins.  
 
ECG and EGCG significantly inhibited the uptake of estrone-3-sulfate by all four OATPs 
at a concentration of 100 µM (Figure 3-2). The U.S. Department of Agriculture Database for the 
Flavonoid Content of Selected Foods reported average concentrations in brewed green tea to be 
19.73 mg/100 ml (450 µM) ECG and 77.81 mg/100 ml (430 µM) EGCG, with the maximal 
concentrations of each catechin in the low millimolar range (U.S. Department of Agriculture, 
www.nal.usda.gov/fnic/foodcomp/Data/Flav/Flav02-1.pdf). These compounds inhibited estrone-
3-sulfate uptake by OATP1A2 and OATP2B1, expressed at the lumen of enterocytes, with IC50 
values ranging from 10 to 100 µM (Figure 3-2). Assuming a gastric fluid volume of 100 to 500 
ml, drinking a cup or two of tea on an empty stomach would result in intestinal concentrations of 
ECG and EGCG within the range that alters OATP transport. The physiological relevance of 
altered OATP1B1 and OATP1B3 transport is more ambiguous, because the bioavailability of 
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catechins is low. A single-dose study in healthy volunteers showed that consumption of 1600 mg 
of EGCG resulted in mean peak plasma concentrations (Cmax) of 7.4 µM, with values ranging 
from 5.8 to 11.3 µM (Ullmann et al., 2003). The IC50 and EC50 values of EGCG on OATP1B3-
mediated uptake of Fluo-3 and estrone-3-sulfate (8.4 and 10.5 µM, respectively) and on 
OATP1B1-mediated transport of estrone-3-sulfate (IC50 = 7.8 µM), are well within this range, 
indicating the physiological relevance of these interactions for those who take high-dose 
supplements. The same authors found that daily consumption of 800 mg of EGCG resulted in an 
average Cmax of 5.3 µM after 10 days (Ullmann et al., 2004). In addition, the bioavailability of 
EGCG was shown to increase with increasing doses, indicating that a saturable presystemic 
elimination process is involved in the low systemic bioavailability (Chow et al., 2001). If this 
presystemic elimination occurs via the liver, the OATP1B1- and OATP1B3-expressing 
hepatocytes may be exposed to these EGCG concentrations at more moderate doses as well.  
 
We identified both ECG and EGCG as novel substrates for OATP1A2 and OATP1B3 
(Figs. 3-5 and 3-6). It is important to note that although these two catechins were inhibitors of 
OATP1B1 and OATP2B1 (Figs. 3-1 and 3-2), we did not see any uptake by either of these 
OATPs (Figure 3-5). This result corroborates the finding that many inhibitors of transporters are 
not substrates of those transporters. It has been shown that ECG and EGCG are taken up into 
Caco-2 cells and that uptake of ECG was saturable and stimulated by low pH (Vaidyanathan and 
Walle, 2003). The authors suggested that this transport was mediated by the monocarboxylate 
transporter MCT1 (Vaidyanathan and Walle, 2003). However, direct transport of ECG or EGCG 
by MCT1 to our knowledge has not been reported, and so far no uptake transporter has been 
identified for green tea catechins. Given that OATP1A2 is expressed in enterocytes, our results 
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suggest that OATP1A2 could be involved in the absorption of ECG and EGCG from the gut. 
Furthermore, given that OATP1A2 can transport numerous drugs including fexofenadine 
(Cvetkovic et al., 1999), several antibiotics such as levofloxacin (Maeda et al., 2007), 
methotrexate (Badagnani et al., 2006), statins (Fujino et al., 2005; Ho et al., 2006), and talinolol 
(Shirasaka et al., 2010), there is the potential for food-drug interactions such as the ones 
described for fruit juices (Dresser et al., 2002; Lilja et al., 2004; Greenblatt, 2009) in patients that 
complement their prescription drugs with over-the-counter green tea supplements. A similar 
danger may exist for OATP1B3. It is not known whether the low systemic bioavailability of 
ECG and EGCG is due to efflux from enterocytes or to a high first-pass effect. However, 
efficient uptake via OATP1B3 into hepatocytes could contribute to the low bioavailability of 
these compounds.  
 
This study clearly demonstrates that OATP-mediated transport may be affected in 
different ways by the same compound, depending on the substrate being transported. We found 
that ECG inhibited OATP1B3-mediated uptake of estrone-3-sulfate, estradiol-17β-glucuronide, 
and Fluo-3, but to very different extents (Figure 3-3A). Inhibition of estrone-3-sulfate transport 
was too weak to further characterize; however, estradiol-17β-glucuronide and Fluo-3 were both 
inhibited in a noncompetitive manner. EGCG, which differs from ECG by a single hydroxyl 
group, stimulated OATP1B3 activity with respect to estrone-3-sulfate transport, inhibited 
transport of Fluo-3, and had no effect on the transport of estradiol-17β-glucuronide (Figure 3-
3B). Uptake of Fluo-3 was noncompetitively inhibited, as was uptake of estrone-3-sulfate at high 
substrate concentrations. The stimulation of estrone-3-sulfate at low substrate concentrations was 
found to be caused by increased substrate affinity. In addition, although 100 µM ECG did not 
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inhibit OATP1B3-mediated estrone-3-sulfate uptake and although EGCG did not affect 
OATP1B3-mediated estradiol-17β-glucuronide uptake, both catechins are substrates of 
OATP1B3 (Figs. 3-1, 3-5, and 3-6). Together, these results suggest the presence of multiple 
substrate binding sites or translocation pathways on OATP1B3.  
 
These results emphasize that, at least in the case of OATP1B1- and OATP1B3-mediated 
transport, it is crucial to test more than one substrate when screening for potential inhibitors. The 
International Transporter Consortium recently suggested that possible OATP inhibition by new 
molecular entities should be tested using a prototypical substrate such as estradiol-17β-
glucuronide (Giacomini et al., 2010). However, we showed that OATP1B3-mediated uptake of 
estradiol-17β-glucuronide was not affected by EGCG, whereas uptake of Fluo-3 was inhibited 
and uptake of estrone-3-sulfate was stimulated (Figure 3-3). Likewise, although a previous study 
found that EGC inhibited OATP1B1-mediated uptake of dehydroepiandrosterone sulfate (Wang 
et al., 2005b), we did not see significant inhibition of OATP1B1-mediated uptake of estrone-3-
sulfate in the presence of EGC. Thus, we propose that for OATP1B1 and OATP1B3, the effect 
of potential inhibitors should always be tested by using several substrates instead of a single 
prototypical substrate. Similar substrate-dependent effects have previously been observed for rat 
Oatp1a4 (Sugiyama et al., 2002), for human OATP1B1 (Noe et al., 2007), and for human 
OATP1B3 (Gui et al., 2008). In our previous study (Gui et al., 2008), the non-OATP substrate 
clotrimazole stimulated OATP1B3-mediated estradiol-17β-glucuronide uptake, did not affect 
uptake of estrone-3-sulfate, and inhibited uptake of Fluo-3. Together, these data clearly 
demonstrate that stimulation as well as inhibition are substrate-dependent and indicate the 
presence of multiple substrate binding sites.  
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A previous study showed inhibition of OATP2B1-mediated uptake of estrone-3-sulfate 
by all four catechins (Fuchikami et al., 2006). However, we found that only ECG and EGCG 
significantly inhibit OATP2B1-mediated estrone-3-sulfate transport. These differences could be 
explained by the 10-fold higher substrate concentration used in the current study and highlights 
the difficulty in predicting in vivo effects based on in vitro data. However, in both studies the 
effects of EC and EGC on OATP2B1-mediated transport were much weaker than the effects of 
ECG and EGCG, suggesting that ECG and EGCG are the green tea catechins most likely to alter 
OATP-mediated drug uptake.  
 
In conclusion, we have demonstrated that the green tea compounds ECG and EGCG are 
substrates for OATP1A2 and OATP1B3 suggesting that these two transporters could be involved 
in the disposition of these two catechins. We also demonstrated that compounds such as ECG 
and EGCG can affect OATPs in a substrate-dependent manner. This finding highlights the 
importance of using multiple and clinically relevant substrates when screening for potential drug-
drug interactions with this family of transporters. Because of increasing use of green tea 
catechins, particularly EGCG, in dietary supplements and because ECG and EGCG can 
significantly alter the function of OATPs involved in drug disposition, the results of this study 
suggest that there is a significant possibility of adverse drug-catechin interactions.  
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Chapter 4 
Isolation of modulators of the liver specific 
Organic Anion Transporting Polypeptides (OATPs) 1B1 and 1B3 from 
Rollinia emarginata Schlecht (Annonaceae) 
 
4.1 Abstract 
 
Organic anion transporting polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3) are 
liver-specific transporters that mediate the uptake of a broad range of drugs into hepatocytes, 
including statins, antibiotics and many anticancer drugs. Compounds which alter transport by 
one or both of these OATPs could potentially be used to target drugs to hepatocytes or to 
improve bioavailability of drugs that are cleared by the liver. In this study, we applied a bioassay 
guided isolation approach to identify such compounds from the organic extract of Rollinia 
emarginata Schlecht (Annonaceae). Fractions of the plant extract were screened for effects on 
OATP1B1- and OATP1B3-mediated transport of the model substrates estradiol-17β-glucuronide 
and estrone-3-sulfate. We isolated three compounds, ursolic acid, oleanolic acid, and 8-trans-p-
coumaroyloxy-α-terpineol, which inhibited estradiol-17β-glucuronide uptake by OATP1B1 but 
not OATP1B3. In addition, a rare compound, quercetin 3-O-α-L-arabinopyranosyl(1→2) α-L-  
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rhamnopyranoside, was identified that had distinct effects on each OATP. OATP1B1 was 
strongly inhibited, as was OATP1B3-mediated transport of estradiol-17β-glucuronide. However, 
OATP1B3-mediated uptake of estrone-3-sulfate was stimulated 4- to 5-fold. Kinetic analysis of 
this stimulation revealed that the apparent affinity for estrone-3-sulfate was increased (decreased 
Km) while the maximal rate of transport (Vmax) was significantly reduced. These results 
demonstrate a mechanism through which the hepatic uptake of drug OATP substrates could be 
stimulated. 
 
4.2 Introduction 
 
Organic anion transporting polypeptides (OATPs) are multispecific transporters that 
mediate the uptake of a broad range of drugs and other xenobiotics into cells. Two members of 
this superfamily, OATP1B1 and OATP1B3, are selectively expressed on the basolateral 
membrane of hepatocytes under normal physiological conditions. Among the substrates of 
OATP1B1 and OATP1B3 are numerous drugs used to treat hypertension, hypercholesterolemia, 
and diabetes (Hagenbuch and Gui, 2008). 
 
Due to the localization of OATP1B1 and OATP1B3 at the basolateral membrane of 
hepatocytes, these transporters can have a significant impact upon the first-pass effect of orally 
administered drugs. Alterations in the function of these OATPs have been shown to affect the 
disposition of drugs throughout the body. Polymorphisms in OATP1B1 have been associated 
with altered pharmacokinetics of several of the HMG-CoA reductase inhibitors (statins). Patients 
with OATP1B1*1b have lower plasma levels of pravastatin and pitavastatin than those with the 
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*1a variant, while the *15 variant is associated with higher plasma concentrations (Nishizato et 
al., 2003; Chung et al., 2005; Maeda et al., 2006a). OATPs have also been implicated as a cause 
of several known drug-drug interactions, including those between cerivastatin and gemfibrozil 
(Shitara et al., 2003), rosuvastatin and cyclosporine (Simonson et al., 2004), and fexofenadine 
and grapefruit juice (Bailey et al., 2007). This suggests that interactions at OATP1B1 or 
OATP1B3 may alter the disposition of drugs throughout the body. 
 
Co-administration of a drug with a small molecule that alters transporter function can be 
used therapeutically to improve drug bioavailability or distribution. The bioavailability of orally 
administered paclitaxel and docetaxel is improved by co-administration with Cyclosporin A, 
which inhibits P-gp-mediated efflux from enterocytes (Meerum Terwogt et al., 1998; Malingre et 
al., 2001). Similarly, co-administration of the BCRP and P-gp inhibitor GF120918 with 
topotecan increased systemic bioavailability two-fold when dosed orally (Kruijtzer et al., 2002). 
Just as inhibiting efflux from enterocytes can increase systemic bioavailability, so could 
inhibiting the first-pass effect of uptake into the liver. Selective inhibition of OATP1B1 or 
OATP1B3 could therefore be used to increase the systemic bioavailability of OATP drug 
substrates. Conversely, selective stimulation of OATP1B1 or OATP1B3 uptake could be used to 
increase drug delivery to hepatocytes.  
 
Among the many OATP substrates are several anticancer drugs, such as docetaxel and 
paclitaxel (OATP1B3) (Smith et al., 2005a), methotrexate (OATP1B1 and OATP1B3) (Abe et 
al., 2001), and the active metabolite of irinotecan, SN-38 (OATP1B1) (Nozawa et al., 2005a). 
Thus, stimulation of OATP1B1 or OATP1B3 transport activity could also be a method of 
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improving cancer treatments. Recently, OATP1B1 and OATP1B3 have also been identified in 
certain cancer tissues, including cancers of the breast, colon, lung, pancreas, prostate, and 
stomach (Abe et al., 2001; Monks et al., 2007; Muto et al., 2007; Hamada et al., 2008). Most of 
these studies have only identified mRNA expression, and neither membrane localization nor 
function has been shown. However, if OATPs are expressed and functional on the surface of 
these cancer cells, stimulation of OATP function could be a promising technique for increasing 
uptake of cytotoxic drugs into cancer cells. 
 
So far, specific modulators of OATPs are limited. One method for identifying additional 
specific modulators is using high throughput screening (HTS). A recent HTS method for 
detecting OATP1B3 modulators identified several compounds that preferentially modulated 
OATP1B1 or OATP1B3, however this assay is not sufficiently stringent for OATP1B1 (Gui et 
al., 2010). Another way to identify modulators is through bioassay-guided fractionation. This is a 
technique frequently used to identify active compounds from plants. Plants are a potentially rich 
source of OATP modulators - herbal extracts used in dietary supplements have been found to 
affect transport by OATP1B1, OATP1B3 (Roth et al., 2011) and by OATP2B1 (Fuchikami et al., 
2006), and interactions between OATPs and fruit juices are well-documented (Dresser et al., 
2002; Bailey et al., 2007; Glaeser et al., 2007; Greenblatt, 2009).  
 
In this study, we applied a bioassay guided isolation approach to identify OATP 
modulators from Rollinia emarginata Schlecht (Annonaceae), a plant that grows in several 
regions of South America. This plant extract was a positive hit during an initial screening of 
several South American plant extracts for their effect on OATP-mediated transport. The stem 
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barks have been used in combination with Ilex paraguayensis St Hilaire (Aquifoliaceae) 
(common name: hierba mate), to treat migraine and as a relaxant. In addition, antiprotozoal and 
antifeedant properties have been reported (Fevrier et al., 1999; Colom et al., 2007). Fractions of 
plant extract were screened for effects on OATP1B1- and OATP1B3-mediated uptake of the two 
model substrates estradiol-17β-glucuronide and estrone-3-sulfate.  
 
4.3: Results 
 
4.3.1: Identification of Compounds with Modulating Effects on OATP1B1 and OATP1B3.  
 
To identify components of Rollinia emarginata that affect OATP1B1 and OATP1B3 
function, the organic components were extracted with MeOH:CH2Cl2, and fractionated with 
various solvents (Figure 4-1). Fractions were solubilized in DMSO, and functional assays were 
performed in triplicate on 96-well plates. Two model substrates, estradiol-17β-glucuronide 
(OATP1B1: Km = 5.4 µM; OATP1B3: Km = 15.8 µM) and estrone-3-sulfate (OATP1B1 high 
affinity component: Km = 0.22 µM; OATP1B3: Km = 58 µM) (Gui et al., 2008; Gui et al., 2009) 
were used to identify compounds that have substrate-dependent effects on transport. Active 
fractions were identified by co-incubating wild-type or OATP-expressing cells with uptake 
buffer containing 0.03 µg/ml Rollinia emarginata extracts and 0.1 µM estradiol-17β-glucuronide 
or 1 µM estrone-3-sulfate for 5 minutes at 37˚C. Results from selected fractions are shown in 
Figure 4-2. The whole plant extract inhibited uptake of both substrates by both transporters; 
detannification increased the inhibitory effect, possibly due to increased availability of formerly 
tannin-bound compounds (data not shown). The hexane (HEX) and butanol (BUOH) fractions  
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Figure 4-1a: 
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Figure 4-1b: 
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Figure 4-1: Separation diagram of Rollinia emarginata organic extract. 
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both showed preferential inhibition of OATP1B1-mediated transport of estradiol-17β-
glucuronide (Figure 4-2A), and were further fractionated. An active subfraction of the hexane 
fraction (data not shown) contained four compounds, which were identified as (1) ursolic acid, 
(2) oleanolic acid, (3) β-sitosterol, and (4) 8-trans-p-coumaroyloxy-α-terpineol (Compound 4). 
Ursolic acid, oleanolic acid, and Compound 4 inhibited OATP1B1 transport of estradiol-17β-
glucuronide by more than 50% while having a minimal effect on OATP1B1 transport of estrone-
3-sulfate (Figure 4-2). The butanol fraction contained a subfraction (Frac B) that strongly 
stimulated uptake of estrone-3-sulfate by OATP1B3, while inhibiting uptake of estradiol-17β-
glucuronide by both OATPs. Frac B was found to mainly consist of two structurally similar 
compounds: (5) rutin and (6) quercetin 3-Ο-α-L-arabinopyranosyl (1→2) α-L-
rhamnopyranoside (Compound 6; Figure 4-3). Compound 6 stimulated uptake of estrone-3-
sulfate by OATP1B3, while inhibiting uptake of estrone-3-sulfate by OATP1B1 (Figure 4-2B) 
and uptake of estradiol-17β-glucuronide by both transporters (Figure 4-2A). To further examine 
the effects of these compounds on OATP-mediated transport, we purified ursolic acid, oleanolic 
acid, Compound 4 and Compound 6 to greater than 95% by HPLC analysis, and used these 
purified compounds for all additional experiments. 
 
4.3.2: Ursolic Acid, Oleanolic Acid, and 8-trans-p-coumaroyloxy-α-terpineol Selectively 
Inhibit OATP1B1-Mediated Transport of Estradiol-17β-glucuronide.  
 
To examine the selectivity of inhibition of the three compounds isolated from the hexane 
fraction, OATP1B1- and OATP1B3-mediated transport of 0.1 µM estradiol-17β-glucuronide or 
estrone-3-sulfate was measured for 20 seconds at 37˚C in the presence of 100 µM ursolic acid,  
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Figure 4-2a: 
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Figure 4-2b: 
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Figure 4-2:  
 
Effect of Rollina emarginata extract and fractions on OATP1B1- and OATP1B3–mediated 
uptake. Cells were coincubated for 5 minutes with 0.1 µM 3H-estradiol-17β-glucuronide (a) or 1 
µM 3H-estrone-3-sulfate (b) and 0.03 µg/ml of plant extract or fraction or 100 µM pure 
compound (1-6). After subtracting the values obtained in wild type cells from those obtained by 
OATP1B1- or OATP1B3-expressing cells, net transporter-mediated uptake was expressed as a 
percentage of the vehicle control (1% DMSO). Each value is the mean ± SD from one 
experiment done in triplicate. Separation steps from initial extract to pure compounds are shown 
with arrows.  
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Figure 4-3:  
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Figure 4-3:  
 
Chemical structures of OATP modulators isolated from Rollina emarginata butanol 
fraction. Compounds were identified as: (5) rutin and (6) quercetin 3-O-α-L-
arabinopyranosyl(1→2) α-L-rhamnopyranoside (Compound 6).  
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oleanolic acid, 8-trans-p-coumaroyloxy-α-terpineol (Compound 4), or 1% DMSO (vehicle 
control). All three compounds significantly inhibited uptake of estradiol-17β-glucuronide by 
OATP1B1 (p < 0.001), while having no effect on uptake by OATP1B3 (Figure 4-4A). 
Compound 4 had a similar effect on uptake of estrone-3-sulfate, inhibiting OATP1B1- but not 
OATP1B3-mediated transport (Figure 4-4B). However, uptake of estrone-3-sulfate by both 
transporters was inhibited to an equal extent by ursolic acid and oleanolic acid (Figure 4-4B). 
Inhibition of estradiol-17β-glucuronide transport by OATP1B1 was further studied with a 
concentration dependency. Ursolic acid and oleanolic acid inhibited uptake of estradiol-17β-
glucuronide with IC50 values of 15.3 µM (Figure 4-5A) and 4.2 µM (Figure 4-5B). Compound 4 
was the weakest inhibitor; the full plateau of inhibition could not be determined due to limited 
solubility (Figure 4-5C).  
 
4.3.3: Quercetin 3-Ο-α-L-arabinopyranosyl (1→2) α-L-rhamnopyranoside has 
Concentration-dependent Effects on OATP1B1- and OAPT1B3-mediated Uptake.  
 
To further investigate the substrate-dependent effects of quercetin 3-Ο-α-L-
arabinopyranosyl (1→2) α-L-rhamnopyranoside (Compound 6), uptake of 0.1 µM estradiol-17β-
glucuronide or estrone-3-sulfate by OATP1B1 and OATP1B3 was measured for 20 seconds at 
37˚C in the presence of increasing concentrations of Compound 6. Uptake of estradiol-17β-
glucuronide was inhibited by Compound 6 to a similar extent for both transporters (Figure 4-6A, 
6B). OATP1B1-mediated uptake of estrone-3-sulfate was inhibited to a lesser extent (IC50 = 130 
µM, Figure 4-6C). The stimulation of OATP1B3-mediated uptake of estrone-3-sulfate was also 
concentration dependent, with an EC50 of 6.8 µM (Figure 4-6D). At concentrations higher than  
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Figure 4-4: 
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Figure 4-4: 
 
Effect of ursolic acid, oleanolic acid, and 8-trans-p-coumaroyloxy-α-terpineol on OATP-
mediated uptake. Cells were coincubated with 0.1 µM 3H-estradiol-17β-glucuronide (E17β; A) 
or 3H-estrone-3-sulfate (E3S; B) and 100 µM ursolic acid, oleanolic acid, or 8-trans-p-
coumaroyloxy-α-terpineol (Compound 4) for 20 seconds. After subtracting the values obtained 
in wild type cells from those obtained by OATP1B1- or OATP1B3-expressing cells, net 
transporter-mediated uptake was expressed as a percentage of the vehicle control (1% DMSO). 
Each value is the mean ± SEM of three independent experiments, each performed in triplicate. 
Asterisks (***) represent statistically significant differences (P < 0.001) from the vehicle control, 
daggers (†††) represent statistically significant differences (P < 0.001) between OATP1B1 and 
OATP1B3.  
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Figure 4-5: 
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Figure 4-5: 
 
Concentration-dependent effect of ursolic acid, oleanolic acid, and Compound 4 on 
OATP1B1-mediated uptake of estradiol-17β-glucuronide. Cells were coincubated with 0.1 
µM 3H-estradiol-17β-glucuronide (E17β) and increasing conentrations of ursolic acid (A), 
oleanolic acid (B), or Compound 4 (C) for 20 seconds. After subtracting the values obtained in 
wild type cells from those obtained by OATP1B1-expressing cells, net transporter-mediated 
uptake was expressed as a percentage of the vehicle control (1% DMSO). Each value shown is 
the mean ± SEM of three independent experiments, each performed in triplicate. 
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100 µM, the effect of Compound 6 on estrone-3-sulfate decreased, although it remained 
stimulatory to the highest tested concentration of 1 mM Compound 6 (data not shown). 
 
4.3.4: Quercetin 3-Ο-α-L-arabinopyranosyl (1→2) α-L-rhamnopyranoside Decreases 
OATP1B3’s Maximal Transport Rate for Estradiol-17β-glucuronide and Estrone-3-sulfate, 
and Increases its Affinity for Estrone-3-sulfate.  
 
To characterize the mechanism by which these four compounds interact with OATP1B1 
and OATP1B3, we examined their effects on the kinetic parameters of OATP1B-mediated 
transport. Kinetic analysis of estradiol-17β-glucuronide and estrone-3-sulfate uptake was 
performed in the presence of each interacting compound or the vehicle control, and results are 
shown in Table 4-1. The affinity of estradiol-17β-glucuronide for OATP1B1 was slightly 
decreased by each of the four substrates tested. The maximal rate of transport (Vmax) was not 
changed by ursolic acid or Compound 4, but was somewhat decreased by both oleanolic acid and 
Compound 6. However, none of these changes reached statistical significance. In initial 
experiments, we determined that ursolic acid, oleanolic acid, and Compound 4 did not alter the 
low-affinity, high-capacity component of OATP1B1-mediated transport of estrone-3-sulfate 
(data not shown); therefore only the high-affinity component was studied. As for estradiol-17β-
glucuronide transport, all four compounds caused small but non-significant decreases in substrate 
affinity, although none altered the maximal rate of transport. 
 
	  
	  
	  94	  
Figure 4-6:  
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Figure 4-6:  
 
Concentration-dependent effect of Compound 6 on OATP-mediated uptake of estradiol-
17β-glucuronide and estrone-3-sulfate. Cells were coincubated with 0.1 µM 3H-estradiol-17β-
glucuronide (E17β; A, B) or 3H-estrone-3-sulfate (E3S; C,D) and increasing concentrations of 
Compound 6 under for 20 seconds. After subtracting the values obtained in wild type cells from 
those obtained by OATP1B1- (A, C) or OATP1B3-expressing cells (B, D), net transporter-
mediated uptake was expressed as a percentage of the vehicle control (1% DMSO). Each value 
shown is the mean ± SEM of three independent experiments, each performed in triplicate. 
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At the substrate concentrations necessary to determine the kinetics of estrone-3-sulfate 
uptake by OATP1B3, ursolic acid and oleanolic acid had no effect on transport. Compound 6, 
however, significantly altered the kinetic parameters of OATP1B3-mediated transport of both 
model substrates, as illustrated in Figure 4-7. OATP1B3-mediated estradiol-17β-glucuronide 
uptake was inhibited in a non-competitive manner (Figure 4-7A). Inclusion of 25 µM (squares) 
or 75 µM (triangles) Compound 6 in the uptake media decreased the maximal rate of transport 
(Vmax) from 280 ± 45 to 188 ± 40 (not statistically significant) and 83 ± 9 pmol/mg*min (p < 
0.05), respectively. Compound 6 had no effect on the apparent affinity (Km) for estradiol-17β-
glucuronide (16 ± 9, 17 ± 5, and 18 ± 9 µM, respectively). Uptake of estrone-3-sulfate by 
OATP1B3 was measured in the presence of 50 µM Compound 6 or 1% DMSO (Figure 4-7B). 
As was the case with estradiol-17β-glucuronide, the Vmax was decreased, from 2.12 ± 0.34 to 
1.07 ± 0.05 nmol/mg*min (p < 0.05). However, the Km was also decreased nearly 10-fold, from 
93 ± 38 µM to 15 ± 3 µM (p < 0.005). This explains the stimulation of transport seen at low 
estrone-3-sulfate concentrations despite the decrease in Vmax. 
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Table 4.1a:  
 
OATP1B1    
Substrate Inhibitor Km (µM) Vmax (pmol/mg protein/min) 
Estradiol-17β-
glucuronide 
None 7 ± 1 175 ± 11 
 Ursolic acid 20 ± 11 217 ± 60 
 Oleanolic acid 13 ± 3 117 ± 10 
 Compound 4 36 ± 19 258 ± 86 
 Compound 6 15 ± 6 92 ± 18 
Estrone-3-sulfate1 None 0.5 ± 0.1 96 ± 10 
 Ursolic acid 0.8 ± 0.1 105 ± 8 
 Oleanolic acid 0.7 ± 0.1 85 ± 5 
 Compound 4 1.3 ± 0.3 102 ± 10 
 Compound 6 0.8 ± 0.2 93 ± 8 
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Table 4.1b: 
	  
OATP1B3    
Substrate Inhibitor Km (µM) Vmax (pmol/mg protein/min) 
Estradiol-17β-
glucuronide 
None 16 ± 9 280 ± 45 
 Ursolic acid n/a n/a 
 Oleanolic acid n/a n/a 
 Compound 4 n/a n/a 
 Compound 6  
(25 µM) 
17 ± 5 188 ± 40 
 Compound 6  
(75 µM) 
18 ± 9 83 ± 9* 
Estrone-3-sulfate1 None 93 ± 38 2120 ± 340 
 Ursolic acid --- --- 
 Oleanolic acid --- --- 
 Compound 4 n/a n/a 
 Compound 6  
(50 µM) 
15 ± 3** 1070 ± 50 
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Table 4.1:  
 
Kinetics of OATP-mediated transport in the absence and presence of modulators. All 
inhibitors were used at 100 µM unless indicated. 1 high affinity component; * = p < 0.05; ** = p 
< 0.005; n/a = no significant inhibition of 0.1 µM substrate by 100 µM inhibitor; --- = no 
apparent inhibition at the concentrations required to determine kinetics 
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Figure 4-7:  
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Figure 4-7:  
 
Effect of Compound 6 on OATP1B3-mediated transport. A. Cells were incubated with 
increasing concentrations of estradiol-17β-glucuronide (E17β) in the presence of 25 µM 
(squares) or 75 µM (triangles) quercetin 3-O-α-L-arabinopyranosyl (1→2)α-L-
rhamnopyranoside (Compound 6), or the vehicle control (0.5% DMSO, circles) for 20 seconds. 
B. Cells were incubated with increasing concentrations of estrone-3-sulfate (E3S) in the presence 
of 50 µM Compound 6 (squares) or the vehicle control (circles) under initial linear rate 
conditions. After subtracting the values obtained in wild type cells, net transporter-mediated 
uptake was fitted to the Michaelis-Menten equation to determine Km and Vmax values. Each value 
shown is the mean ± SEM of at least three independent experiments, each performed in 
triplicate. 
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4.4: Discussion 
 
Many naturally occurring plant compounds have been identified that interact with OATPs 
(Dresser et al., 2002; Fuchikami et al., 2006; Bailey et al., 2007; Glaeser et al., 2007; Greenblatt, 
2009), making plants a potentially rich source of OATP modulators. In the present study, we 
used a bioassay-guided approach to isolate and identify four compounds from the organic extract 
of Rollinia emarginata Schlecht (Annonaceae) that selectively modulate OATP function. This 
approach enabled us to quickly focus in on fractions of plant extract containing compounds that 
had substrate-specific or transporter-specific effects on OATP function. As is illustrated in 
Figure 4-1, only 3 to 4 fractionation steps were required to isolate pure compounds with the 
desired activity from the plant extract. A downfall of this approach is the likelihood of missing 
OATP modulating compounds, whose effects may be masked in the early stages of fractionation 
due to the large number of compounds in each fraction. However, it does allow for the early 
elimination of many general OATP modulators, increasing the efficiency of this approach when 
compared to that of high-throughput screening of large compound libraries. 
 
 We demonstrated that ursolic acid, oleanolic acid, and Compound 4 selectively inhibit 
estradiol-17β-glucuronide transport by OATP1B1 compared to OATP1B3 (Figure 4-4A). 
Several other compounds have previously been identified as selective inhibitors of OATP1B1. 
Uptake of estradiol-17β-glucuronide by OATP1B1 was inhibited to a greater extent than was 
uptake by OATP1B3 by both indocyanine green (Cui et al., 2001) and the proposed cardiotonic 
agent YM758 (Umehara et al., 2008). Taurocholate uptake by OATP1B1 was inhibited by the 
glycocholic acid derivatives BAPA-8, BAPA-6, and BAPA-3 more strongly than was uptake by 
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OATP1B3 (Vicens et al., 2007). However, we found that the selective inhibition of OATP1B1 
by ursolic acid and oleanolic acid was dependent upon the substrate being transported. While 
Compound 4 selectively inhibited OATP1B1 transport of both estradiol-17β-glucuronide and 
estrone-3-sulfate but had no significant effect on transport by OATP1B3, ursolic acid and 
oleanolic acid inhibited the uptake of estrone-3-sulfate by both transporters (Figure 4-4B). 
Furthermore, in a previous study using fluorescein-methotrexate (FMTX) we identified ursolic 
acid as a preferential OATP1B3 inhibitor (Gui et al., 2010). Ursolic acid inhibited OATP1B3-
mediated FMTX uptake with an IC50 of 2.3 µM while the IC50 value for OATP1B1 was 12.5 
µM. 
 
 Substrate–dependent modulation of OATP1B3 was also produced by Compound 6. 
Transport of estradiol-17β-glucuronide by both OATP1B1 and OATP1B3 was inhibited to the 
same extent (Figures 4-6A, 4-6B). However, uptake of estrone-3-sulfate by OATP1B1 was 
inhibited, while uptake by OATP1B3 was stimulated (Figures 4-6C, 4-6D). Further investigation 
of this effect on OATP1B3 revealed that the maximal rate of transport (Vmax) was reduced for 
both substrates (Figure 4-7). The apparent substrate affinity (Km) for estradiol-17β-glucuronide 
was unchanged, causing inhibition of transport at all concentrations studied. In contrast, the 
affinity for estrone-3-sulfate was increased 10-fold, leading to stimulation of transport at low 
substrate concentrations, and inhibition of transport at high substrate concentrations.  
 
There are many mechanisms by which transporter function may be inhibited or 
stimulated. Changes in the expression of transporter protein on the cell surface, whether through 
transcriptional regulation or post-translational modifications, would affect uptake of all 
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substrates in the same manner, and thus cannot explain the substrate-specific changes in 
transporter activity produced by ursolic acid, oleanolic acid, and Compound 6. Compound 4 
inhibited transport of both substrates by OATP1B1 but not by OATP1B3, which could be 
explained by rapid internalization of OATP1B1. However, the full inhibitory effect described 
here took place during 20 seconds of exposure, whereas phosphorylation-induced internalization 
of OATP2B1 and rat Oatp1a1 proteins appears to take at least 10 to 30 minutes (Kock et al., 
2010; Choi et al., 2011). However, post-translational modifications such as phosphorylation may 
also directly alter activity of a transporter, as is seen with the glucose transporter (Berridge and 
Tan, 1995), and theoretically could do so in a substrate-dependent way. Alternatively, if the 
isolated compounds are substrates of OATP1B1 or OATP1B3, they could exert their effects 
through competitive inhibition. There is considerable evidence that OATPs have multiple 
binding sites, therefore a compound may inhibit uptake of a substrate that shares its binding site 
while having no effect on a substrate that has a distinct binding site. This competitive inhibition 
would be expected to decrease affinity for the substrate that shares a binding site, while not 
affecting the Vmax. Unfortunately, as relatively weak inhibitors, ursolic acid, oleanolic acid and 
Compound 4 did not have statistically significant effects on the kinetic parameters of OATP1B1- 
or OATP1B3-mediated uptake, suggesting that if they are substrates, they are very low-affinity. 
A final explanation for these results is that the compounds may bind to a portion of OATP1B1 or 
OATP1B3, sterically hindering either the binding or the translocation of substrates. In the case of 
R002, this binding could also cause a conformational change in OATP1B3 that increases the 
affinity of the transporter for estrone-3-sulfate while not affecting the estradiol-17β-glucuronide 
binding site.  
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Interestingly, although Compound 6 stimulated transport of estrone-3-sulfate, the 
structurally similar rutin (Compound 5) did not show this effect. However, rutin was previously 
shown to stimulate uptake of 0.5 µM DHEAS by OATP1B1 (Wang et al., 2005b). This 
demonstrates that stimulation of uptake is not a phenomenon specific to OATP1B3, but may be 
shared by all OATPs. This is further supported by a previous study on OATP2B1 where different 
steroids stimulated the uptake of either estrone-3-sulfate or DHEAS by OATP2B1 (Grube et al., 
2006a). Substrate-dependent effects of OATP modulators as shown in this study have also been 
seen previously. We found that EGCG inhibits OATP1B3-mediated uptake of Fluo-3, has no 
effect on uptake of estradiol-17β-glucuronide, and stimulates uptake of estrone-3-sulfate (Roth et 
al., 2011b). We also discovered that clotrimazole stimulates OATP1B3-mediated transport of 
estradiol-17β-glucuronide, inhibits transport of Fluo-3, and has little effect on uptake of estrone-
3-sulfate (Gui et al., 2008). Gemfibrozil inhibits OATP1B1 uptake of pravastatin, fluvastatin, 
simvastatin and taurocholate, but not of estrone-3-sulfate or troglitazone sulfate (Noe et al., 
2007). Low concentrations of rosiglitazone (10 µM) inhibit OATP1B1 and OATP1B3 transport 
of bromosulfophthalein, but stimulate uptake of pravastatin by both transporters (Bachmakov et 
al., 2008).  
 
 Inhibition and stimulation of OATPs can clearly be dependent on the substrate being 
transported. Although there are compounds that can nonspecifically inhibit transport of all OATP 
substrates, as rifampicin seems to do, there are no compounds which selectively inhibit transport 
of all substrates by a single OATP. Using a general OATP inhibitor to reduce the hepatic first-
pass effect of a drug is likely to cause a wide range of effects, due to inhibition of transport of 
other OATP substrates by OATPs expressed throughout the body. Therefore, to be used 
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therapeutically, it is essential to identify compounds that selectively inhibit either OATP1B1 or 
OATP1B3 while having no effect on transport mediated by other OATPs. Ideally, the inhibition 
would also be less potent for endogenous substrates or other drugs like statins than for the drug 
with the disadvantageous first-pass effect. Similarly, to increase uptake of drugs by hepatocytes 
or by OATP-expressing cancer cells, stimulation of OATP transport should be restricted to the 
OATP being targeted, while having little effect on uptake of other substrates by that transporter. 
It is therefore essential to identify selective OATP modulators.  
 
In conclusion, we have identified four compounds that modulate OATP function. Ursolic 
acid, oleanolic acid, and 8-trans-p-coumaroyloxy-α-terpineol, inhibit estradiol-17β-glucuronide 
uptake by OATP1B1 but not by OATP1B3, while ursolic acid and oleanolic acid inhibit estrone-
3-sulfate uptake by both transporters. Quercetin 3-O-α-L-arabinopyranosyl(1→2) α-L-
rhamnopyranoside (Compound 6) inhibits transport by OATP1B1, but has substrate-dependent 
effects on OATP1B3, non-competitively inhibiting uptake of both substrates at high substrate 
concentrations, but stimulating estrone-3-sulfate uptake at low substate concentrations by 
increasing affinity. The results of this study show that plant materials are a good starting point 
for the isolation of OATP modulating compounds, and that a bioassay-guided approach can be 
used to efficiently identify selective OATP modulators. 
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Chapter 5 
Cysteine Scanning Mutagenesis on Transmembrane Domain 1 of the Liver-
Specific Organic Anion Transporting Polypeptide 1B3 (OATP1B3) 
 
5.1: Abstract 
 
The liver-specific organic anion transporting polypeptide 1B3 (OATP1B3) is a 
multispecific transporter that mediates the uptake of a broad range of drugs and other xenobiotics 
into hepatocytes. To identify regions in OATP1B3 important for substrate binding and/or 
translocation, we performed cysteine scanning mutagenesis. Thirty-three amino acids in 
transmembrane domain 1 (TM1) and extracellular loop 1 (ECL1) were individually mutated to 
cysteines, and mutant proteins were transiently expressed in HEK293 cells. To determine the 
effect of each mutation on protein function, we measured uptake of estrone-3-sulfate and 
estradiol-17β-glucuronide. Transport was significantly reduced in several mutants after 
correcting for surface expression, indicating that this stretch of amino acids may be important for 
protein function. Functional cysteine mutants were then incubated with the cysteine-modifying 
reagent sodium (2-sulfonatoethyl)methanethiosulfonate (MTSES) prior to measuring uptake. 
MTSES pre-incubation strongly inhibited the function of those mutants that could be labeled 
with biotinylated maleimide. These data suggest that TM1 and ECL1 in OATP1B3 play a 
significant role in substrate binding and/or translocation. 
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5.2: Introduction 
 
The efficient absorption and distribution of many xenobiotics depends on carrier-
mediated transport through cell membranes. Organic anion transporting polypeptides (OATPs) 
are multispecific transporters that are expressed in epithelia throughout the body and are largely 
responsible for the Na+-independent uptake of large amphipathic organic anions into cells. There 
are eleven human members of the OATP superfamily, classified into six families based on a 40% 
amino acid sequence identity (Hagenbuch and Meier, 2004). Two of these proteins, OATP1B1 
and OATP1B3, are normally exclusively expressed at the basolateral membrane of hepatocytes 
(Abe et al., 1999; Konig et al., 2000a; Konig et al., 2000b; Abe et al., 2001), where they can have 
a significant effect on the first-pass clearance of orally administered drugs. Substrates of 
OATP1B1 and OATP1B3 include both endogenous compounds, such as bile acids, bilirubin, 
steroid conjugates, and thyroid hormones, and numerous xenobiotics, including statins, sartans, 
β-lactam antibiotics, anticancer drugs, fexofenadine and HIV protease inhibitors (Hagenbuch and 
Gui, 2008). 
 
OATP1B1 and OATP1B3 share 80% amino acid identity with each other and have a 
single rodent ortholog, Oatp1b2. Because these three proteins have overlapping but distinct 
substrate specificities, potential drug-drug interactions can be missed in pre-market safety 
testing. OATPs have indeed been implicated in multiple adverse drug-drug interactions (DDIs), 
such as those between cerivastatin and gemfibrozil (Shitara et al., 2003), rosuvastatin and 
cyclosporine (Simonson et al., 2004), and fexofenadine and grapefruit juice (Bailey et al., 2007; 
Glaeser et al., 2007). In addition, OATP1B3 is expressed in a wide variety of cancer cell lines 
	  
	  
	   109	  
and tumors, including cancers of the breast (Muto et al., 2007), lung (Monks et al., 2007), and 
prostate (Hamada et al., 2008), as well as gastric, colon and pancreatic cancers (Abe et al., 2001; 
Lee et al., 2008). Among the many OATP1B3 substrates are several anti-cancer drugs, including 
methotrexate (Abe et al., 2001), the taxanes paclitaxel and docetaxel (Smith et al., 2005a; 
Letschert et al., 2006), imatinib (Hu et al., 2008), and SN-38, the active metabolite of irinotecan 
(Yamaguchi et al., 2008). This raises the possibility that cytotoxic OATP1B3 substrates may be 
targeted to tumor tissues.  
 
OATP1B3 is a 691 amino acid glycoprotein with an apparent molecular mass of 120 
kDa, which is reduced to about 60 kDa after deglycosylation. Like all OATPs, OATP1B3 is 
predicted to contain 12 transmembrane domains with both termini located in the cytosol (Wang 
et al., 2008). However, due to the lack of a crystal structure, little is known about either the 
three-dimensional structure of OATPs or the mechanism by which they bind and transport 
substrates. Multiple groups have created homology models for OATP1B3 based on the crystal 
structures of the glycerol-3-phospate transporter and lactose permease (Meier-Abt et al., 2005; 
Glaeser et al., 2010; Frandoloso et al., 2011) or the glycerol-3-phosphate transporter and 
multidrug transporter EmrD (Gui and Hagenbuch, 2008). These models suggest that the 
transmembrane domains of OATP1B3 form a central positively charged pore. Numerous amino 
acids within this pore have been identified as important for transport, including the positively 
charged K41 and R580 (Glaeser et al., 2010), and K361 (Mandery et al., 2011). Similar studies 
with OATP1B1 confirmed that the positively charged K361 and R580 are involved in transport 
by both OATP1B family members, as well as identifying a positive charge at R57 as being 
essential for OATP1B1 transport (Weaver and Hagenbuch, 2010). In addition, chimera studies 
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between OATP1B1 and OATP1B3 identified several neutral amino acids in transmembrane 
domain 10 that are important for transport of the OATP1B3-specific substrate cholecystokinin 
octapeptide (CCK-8), possibly due to their involvement in forming hydrogen bonds with the 
substrate (Gui and Hagenbuch, 2008). The same study indicated that replacing TM1 of 
OATP1B3 with the corresponding transmembrane domain from OATP1B1 resulted in a greater 
than 50% loss of function for CCK-8 transport. This, combined with the findings that K41 in 
OATP1B3 and R57 in OATP1B1 are important for transporter function, suggests that 
transmembrane domain 1 of the OATP1B family forms part of the positively charged central 
pore, and provides critical interactions with the substrates. To further study the role of this region 
in the binding and translocation of substrates, we performed cysteine scanning mutagenesis 
studies on the first transmembrane domain and extracellular loop of OATP1B3. Our results 
indicate that TM1 does form part of the substrate translocation pathway, and that both TM1 and 
ECL1 contain numerous amino acids that are important for substrate transport. 
 
5.3: Results 
 
5.3.1 Cysteine Scanning Mutagenesis of OATP1B3.  
 
OATP1B3 is predicted to have twelve transmembrane domains, with both termini being 
located in the cytoplasm. Previous studies have indicated that amino acids in the first 
transmembrane domain (TM1) and extracellular loop (ECL1) are important for transport 
function of OATP1B3. To determine the role that amino acids in TM1 and ECL1 of OATP1B3 
play in substrate recognition and translocation, we performed cysteine scanning mutagenesis. 
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Thirty-three amino acids predicted to be located in the first transmembrane domain (TM1) and 
extracellular loop (ECL1) were individually mutated into cysteines (M29 – S62, Figure 5-1). 
Mutant Q54C could not be propagated and is not included in the analysis. Vectors containing 
wild-type or mutant OATP1B3 were transiently expressed in HEK293 cells. To measure the 
level of surface expression of each mutant, we biotinylated and purified surface proteins and 
performed a western blot, detecting OATP1B3 expression using an anti-His antibody. Western 
blots were also probed with an antibody against the alpha subunit of Na+/K+ ATPase, as a control 
for biotinylation. OATP1B3 and all mutant proteins were expressed on the cell surface to 
approximately the same extent (Figure 5-2). 
 
5.3.2: Function of Cysteine-Substituted Mutants.  
 
Due to observed differences in substrate specificity, we screened all cysteine-substituted 
mutants for transport activity by measuring uptake of two different radiolabeled model 
substrates: estrone-3-sulfate and estradiol-17β-glucuronide. Uptake of each substrate was 
measured after incubating at 37˚C for 5 minutes, and is expressed for each cysteine mutant as a 
percentage of uptake by wild-type OATP1B3. Most mutant transporters retained at least partial 
transport activity, however six mutants (K41C, K49C, I50C, T53C, I55C and E56C) had very 
little or no transport activity, despite being expressed on the cell surface (Figure 5-3). In general, 
mutations predicted to fall within the cytoplasmic half of the transmembrane domain (M29C-
S37C) had little effect on function, while mutations in the predicted extracellular loop (T53C-
D60C) all caused significant reductions in substrate transported (>50%). Within the area of the  
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Figure 5-1: 
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Figure 5-1: 
 
Predicted transmembrane location of the cysteine-substituted amino acids. Membrane 
topology as predicted from three-dimensional homology model of OATP1B3 (Gui and 
Hagenbuch, 2008). Black filled circles represent naturally occurring cysteine residues; amino 
acids represented by gray filled circles were individually mutated to cysteine (inset). 
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Figure 5-2: 
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Figure 5-2: 
 
Surface expression of cysteine-substituted mutants. HEK293 cells transiently expressing 
wildt-ype or cysteine mutated OATP1B3 were incubated with Sulfo-NHS-SS-Biotin, and surface 
proteins were purified with Neutravidin. Western blots were incubated with monoclonal anti-his 
or anti-Na+/K+ ATPase antibodies. Shown are representative blots of at least three independent 
experiments. 
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Figure 5-3: 
 
	  
	  
	   117	  
Figure 5-3: 
 
Function of cysteine-substituted mutants. Cells were incubated with 0.1 µM 3H-estrone-3-
sulfate (E3S) or 3H-estradiol-17β-glucuronide (E17β) for 5 minutes at 37˚C. After subtracting the 
values obtained in cells expressing the empty vector, uptake was expressed as a percentage of 
wild-type. Each value is the mean ± SEM of three independent experiments. Asterisks represent 
significant differences from the wild-type control (P < 0.05). 
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protein predicted to be in the extracellular half of the transmembrane domain, cysteine 
substitutions at positions 38, 41, 45, 49 and 50 decreased activity, while substitutions in the 
remaining positions (39-40, 42-44, 46-48, and 51-52) did not. Interestingly, uptake of estrone-3-
sulfate by the I47C mutant was significantly increased when compared to wild type. In addition, 
the effect on transport of estradiol-17β-glucuronide was significantly different from the effect on 
transport of estrone-3-sulfate for the mutants I46C and I47C. 
 
5.3.3: Effect of MTSES Pre-treatment on Function of Cysteine-Substituted Mutants.  
 
The effect of a given cysteine substitution on OATP1B3 transport activity might be 
dependent on whether the amino acid is exposed to the substrate-containing extracellular 
aqueous environment. To determine whether decreased transport activity was associated with 
solvent accessibility, we investigated whether preincubation with the membrane impermeable 
thiol-specific reagent sodium (2-Sulfonatoethyl)methanethiosulfonate (MTSES) affected 
substrate uptake. Cells expressing wild-type or mutant OATP1B3 proteins were incubated in a 
buffer containing 10 mM MTSES for 10 minutes at 37˚C. After washing, uptake of estrone-3-
sulfate and estradiol-17β-glucuronide was measured as described above. Uptake of each 
substrate after incubation in MTSES is expressed as a percentage of the uptake by the same 
mutant after ten-minute incubations in buffer that did not contain MTSES (Figure 5-4). Four 
mutants that were found to be nearly nonfunctional in the previous experiment (K41C, K49C, 
I50C and E56C) were not tested. Proteins with cysteine substitutions at locations 29-37, which 
are predicted to be in the cytosolic half of the transmembrane domain, were unaffected by pre-  
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Figure 5-4: 
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Figure 5-4: 
 
Effect of MTSES pre-incubation on the function of cysteine-substituted mutants. HEK293 
cells transiently expressing wild-type or cysteine mutated OATP1B3 were incubated with uptake 
buffer containing 10 mM MTSES for 10 min at 37˚C, briefly washed, then incubated with 0.1µM 
3H-estrone-3-sulfate (E3S) or 3H-estradiol-17β-glucuronide (E17β) for 5 minutes at 37˚C. After 
subtracting the values obtained in cells transfected with the empty vector, values were expressed 
as a percentage of the buffer control. Each value is the mean ± SEM of three independent 
experiments. Asterisks represent significant differences (P < 0.05) from buffer controls. 
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incubation with MTSES. Significant reductions in transport was seen after MTSES treatment 
when cysteines were substituted for amino acids at positions 38, 42, 45 – 52, 58, and 61 (Figure 
5-4, asterisks). The effect of MTSES on transport activity was significantly different between the 
two substrates tested for mutants A42C, G45C, I46C, and I52C (Figure 5-4, daggers). 
 
5.3.4: Accessibility of Substituted Cysteines to Aqueous Environment.  
 
Cells expressing wild-type or mutant OATP1B3 proteins were incubated in PBS 
containing maleimide-PEG2-biotin (0.5mg/ml) for 1 hour at 4˚C. Labeled proteins were then 
affinity purified and subjected to western blot anlysis. To ensure equal levels of transfection 
efficiency for each mutant, OATP1B3 protein in the total cleared lysate was also quantified (data 
not shown). As shown in Figure 5-5, cysteines substituted at positions 29-37 were not labeled by 
maleimide-PEG2-biotin, indicating that they are inaccessible from the extracellular environment. 
All cysteine substitutions from positions 52-62 are strongly labeled, supporting their predicted 
localization in the extracellular loop. In addition, several amino acids in the presumptive 
extracellular half of TM1 were also consistently labeled: Y38C, K41C, A42C, I46C, and M48C.  
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Figure 5-5: 
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Figure 5-5: 
 
Accessibility of substituted cysteines to aqueous environment. HEK293 cells transiently 
expressing wild-type or cysteine mutated OATP1B3 were incubated with the membrane-
impermeable, cysteine-specific reagent maleimide-PEG2-biotin for 1 hour at 4˚C, and 
biotinylated proteins were affinity purified with Neutravidin. Western blots were incubated with 
monoclonal anti-his antibodies. Shown are representative blots of at least three independent 
experiments.  
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5.4: Discussion 
 
OATP1B3 is exclusively expressed on the basolateral membrane of hepatocytes under 
normal physiological conditions, and plays a significant role in the first-pass clearance of drugs 
and other xenobiotics from the portal blood. Recently, it has also been shown that OATP1B3 is 
expressed in multiple cancer cell lines and tissues, where it could be involved in the uptake of 
growth-stimulating hormone conjugates or in anticancer drugs. To identify potential adverse 
drug-drug interactions, or to design anticancer drugs that can take advantage of OATP1B3 
expression in cancer cells, we need to have a better understanding of how OATP1B3 recognizes 
and transports substrates. Previous studies have indicated that the first transmembrane domain 
(TM1) of OATP1B3 may form part of the substrate translocation pathway. In this study, we used 
cysteine-scanning mutagenesis to demonstrate that TM1 and the first extracellular loop (ECL1) 
are important for substrate transport. 
 
 It is standard to use a cysteine-less template for all cysteine-scanning mutagenesis 
studies to prevent labeling of native cysteines. However, previous experiments have indicated 
that the cysteines present in OATPs are important for surface expression and/or function. A 
study on OATP2B1 showed that the 10 conserved cysteines in the 5th extracellular loop all 
formed disulfide bonds. Removing this extracellular loop or mutating any of the cysteines into 
alanine resulted in a protein with limited to no surface expression, indicating that the disulfide 
bonds formed by these cysteines may be essential for correct protein folding (Hanggi et al., 
2006). Wild-type OATP1B3 contains 19 cysteine residues, including the ten highly conserved 
cysteines studied on OATP2B1. Three cysteines are predicted to be on the intracellular termini 
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(C24 and C691) or in a transmembrane domain (C101), and therefore are not expected to be 
accessible to the membrane impermeable reagents (black filled circles in Figure 5-1). The 
remaining six cysteines are predicted to be on extracellular loops, with 2 in the second 
extracellular loop, 1 in the large 5th extracellular loop (which has 11 total), and 3 in the final (6th) 
extracellular loop. Despite the presence of these cysteines, wild-type OATP1B3 was both 
unaffected by the MTSES pretreatment and not labeled by maleimide-PEG2-biotin (Figures 5-4 
and 5-5). This suggests that all cysteines found in extracellular loops are involved in disulfide 
bonds or are otherwise unable to react with the maleimide reagent. As it was non-reactive to the 
reagents used, we used the wild-type OATP1B3 as the template for all experiments. 
 
We used a three-dimensional homology model of OATP1B3 (Gui and Hagenbuch, 2008) 
to identify thirty-four amino acids (M29 to S62) predicted to form the first transmembrane 
domain and extracellular loop of OATP1B3. Each amino acid was individually mutated to 
cysteine, with the exception of Q54, which could not be propagated in bacteria when mutated to 
cysteine. When transiently expressed in HEK-293 cells, each of the cysteine mutants was 
expressed on the cell membrane at levels comparable to wild-type OATP1B3 (Figure 5-2). This 
suggests that this region of OATP1B3 is not involved in transport to the cell surface or anchoring 
within the membrane bilayer. In addition, one can conclude that any alterations of substrate 
transport in the mutant proteins are caused by changes in the protein function, rather than by 
altered levels of surface expression. 
 
Studies have suggested that OATP1B3 has distinct binding sites for different substrates. 
The affinity of OATP1B3 for estrone-3-sulfate is significantly increased in the presence of 
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epigallocatechin-gallate (Roth et al., 2011b) or quercetin 3-O-α-L-arabinopyranosyl(12) α-L-
rhamnopyranoside (Roth et al, 2011a), while neither compound affects the affinity for estradiol-
17β-glucuronide. Similarly, rosiglitazone inhibits OATP1B3-mediated uptake of 
bromosulfophthalein while stimulating uptake of pravastatin (Bachmakov et al, 2008), and 
clotrimazone stimulates transport of estradiol-17β-glucuronide by OATP1B3, but has little effect 
on the uptake of estrone-3-sulfate by the same transporter (Gui et al., 2008). To account for the 
possibility that TM1 and ECL1 could play different roles in the transport of different substrates, 
function of the cysteine mutants was determined by measuring transport of two model substrates: 
estradiol-17β-glucuronide and estrone-3-sulfate. Thirteen of the thirty-three mutants had 
significantly reduced transport of at least one substrate. Mutants F30C and G45C had 
significantly reduced transport of estradiol-17β-glucuronide but not of estrone-3-sulfate; 
however, there was no statistical difference when comparing uptake between the two substrates. 
OATP1B3 transports estradiol-17β-glucuronide with a higher affinity (Km = 5 µM to 25 µM) 
than it does estrone-3-sulfate (Km = 60 µM to 100 µM), resulting in a much higher signal-to-
noise ratio for estradiol-17β-glucuronide at the substrate concentration tested (0.1 µM). It is 
likely that the lower signal for estrone-3-sulfate uptake is responsible for the lack of significance 
seen with these two mutants, as it results in higher standard deviations. However, there were 
statistically significant differences between the uptake of estradiol-17β-glucuronide and estrone-
3-sulfate by the mutants I46C and I47C. While estrone-3-sulfate uptake by I47C was 
significantly increased when compared to wild-type OATP1B3, uptake of estradiol-17β-
glucuronide was unaffected by the mutation. The opposite results were caused by the 146C 
mutation: uptake of estrone-3-sulfate was unaffected or slightly inhibited, while transport of 
estradiol-17β-glucuronide was increased, although this did not reach statistical significance. In 
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general, MTSES pretreatment also had a greater inhibitory effect on estradiol-17β-glucuronide 
uptake than it did on estrone-3-sulfate uptake. Four mutants, A42C, G45C, I46C and I52C, had 
significantly greater loss of transport activity for estradiol-17β-glucuronide than for estrone-3-
sulfate after incubation with MTSES. These data support earlier findings that the essential 
interactions between OATP1B3 and its substrates vary by substrate, and could indicate that the 
first transmembrane domain and extracellular loop of OATP1B3 have more significant 
interactions with estradiol-17β-glucuronide than with estrone-3-sulfate. Additional experiments 
are necessary to determine whether these substrate-specific results are caused by alterations in 
the substrate affinity (apparent Km) or in the rate of translocation (Vmax). 
 
The three-dimensional homology model of OATP1B3 (Gui and Hagenbuch, 2008) is 
shown in Figure 5-6. Amino acids from M29 to S62, making up the first transmembrane domain 
and extracellular loop, are shown in green. This model suggests that the extracellular half of the 
transmembrane domain forms part of the central pore. However, the intracellular half is oriented 
towards the membrane bilayer, and may be partially covered by transmembrane domain IV. With 
the exception of F30C, which showed a 50% reduction in function, mutation of the amino acids 
predicted to be in the intracellular half of transmembrane domain I did not result in altered 
transport activity (M29 – S37). Similarly, none of these mutants had altered transport after 
preincubation with MTSES, nor were any labeled by maleimide-PEG2-biotin. These results 
suggest that the intracellular half of TM1 do not form significant interactions with substrate, and 
that they are inaccessible from the extracellular medium, as predicted by the homology model. 
Transport was significantly reduced by cysteine mutagenesis of residues Y38, K41, G45 and 
K49 (Figure 5-3), while the intervening mutants retained function. These four residues make up  
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Figure 5-6: 
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Figure 5-6: 
 
Three-dimensional homology model of OATP1B3 (Gui and Hagenbuch, 2008). A side view 
is shown in (A) and the extracellular view is shown in (B). Residues that were individually 
mutated to cysteines are illustrated in green while the remaining residues are blue. The helical 
wheel analysis (C) was generated with HeliQuest (http://heliquest.ipmc.cnrs.fr/) (Gautier et al., 
2008). The internal black arrow represents the total hydrophobic moment; external arrows are 
described in the text. 
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one face of a transmembrane domain α-helix as predicted by helical wheel analysis (Figure 5-6C, 
black arrows), and are predicted to face the central pore according to the three-dimensional 
homology model. These results suggest that the extracellular portion of transmembrane domain I 
forms part of the substrate translocation pathway, and that the residues facing the central pore 
make interactions that are important for substrate recognition and transport. While transport by 
the I50C construct is also drastically reduced, this residue is located on the opposite and 
hydrophobic face of the predicted α-helix (Figure 5-6C, red arrow). As this amino acid is near 
the extracellular end of the predicted transmembrane domain, it could be that the protein is 
coming out of the α-helix formation. Cysteine substitution at residues 41, 49, 50 and 56 caused 
near abrogation of transport activity; therefore, these mutants could not be tested for the effect of 
MTSES pre-treatment on function. MTSES pre-treatment did reduce transport by the Y38C and 
G45C proteins, as well as A42C, which share the same face of the α-helix (Figure 5-6C, blue 
arrow). Within this region, cysteines substituted for Y38, K41, and A42 were all labeled by 
maleimide-PEG2-biotin, while the intervening residues could not be labeled. This also supports 
the homology model, which predicts that these amino acids line the central pore of the protein, 
and thus could be accessible from the extracellular media. Intervening residues, which were 
neither labeled by maleimide-PEG2-biotin nor affected by MTSES incubation, are predicted to 
face away from the central pore and toward the other transmembrane domains, and therefore 
would be protected from the extracellular environment. 
 
Within and near the predicted extracellular loop, the effect of cysteine substitution is 
more variable. Almost all cysteines inserted at positions 48 through 62 were labeled by 
maleimide-PEG2-biotin (Figure 5-5), demonstrating that these residues are located near the 
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extracellular surface of the protein and therefore are accessible from the extracellular 
environment. Mutants I47C and K49C were labeled less strongly than the other mutant proteins, 
which suggests that their location at the predicted transition from the transmembrane domain to 
the extracellular loop could interfere with the interaction between the inserted cysteine and 
maleimide-PEG2-biotin. Similarly, mutant S51C, which had reduced function after pre-
incubation with MTSES, was not labeled by maleimide PEG2-biotin. This could indicate that this 
residue faces another part of the OATP1B3 protein, with just enough intervening space for the 
small, negatively charged MTSES to interact with the inserted cysteine, while remaining 
inaccessible to the significantly larger, neutral maleimide compound. Numerous residues within 
the predicted extracellular loop appear to form significant interactions with substrates, as all 
cysteine substitutions from positions 53 to 60 caused significant reductions (>50%) in transport 
activity. The reduced function of these mutants makes it difficult to determine whether there is 
an additional effect of MTSES pre-treatment; however, only the R58C mutant had significantly 
reduced function after incubation with MTSES (Figure 5-4). The importance of the residues in 
ECL1 for full function suggests that the extracellular domains of OATP1B3 play a role in 
directing substrates into the central translocation pore. 
 
The results of this study indicate that the extracellular half of TM1 of OATP1B3 forms 
part of the open pore of the protein, as indicated by the homology models. Amino acids that face 
the pore are important for function, and modifying these with MTSES causes a further decrease 
in function. Amino acids on the extracellular loop appear to play a varying role in directing 
substrate into the pore.  
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Chapter 6 
Summary and Discussion 
 
6.1: Significance 
 
Organic anion transporting polypeptides (OATPs) are multispecific transporters that 
mediate the uptake of a broad range of drugs and other xenobiotics into cells. OATP1B1 and 
OATP1B3 are exclusively expressed at the basolateral membrane of hepatocytes under normal 
phsyiological conditions. With this localization, these proteins are involved in the first-pass 
clearance of drugs from the portal blood into the liver, and thus play an important role in 
determining the pharmacokinetic profile of many drug substrates. Polymorphisms in these 
transporters have been associated with altered pharmacokinetics of many drug substrates, such as 
statins and antidiabetic agents, demonstrating their importance to drug disposition. Drug-drug or 
drug-food interactions at OATPs can also alter the pharmacokinetic profiles of these or other 
substrates, leading to decreased efficacy or increased toxicity. In addition, OATP1B3, which 
transports numerous anticancer drugs, is expressed in a wide variety of cancer tissues and cell 
lines. Altering OATP1B3-mediated transport by co-administration with small molecules could 
be used to target anticancer drugs to the OATP1B3-expressing cancer tissues. 
 
Due to the limited structural information available for OATPs, little is known about the 
mechanism of substrate binding and translocation. Subsequently, little is known about the 
mechanism of drug-drug interactions or drug-food interactions that occur at OATPs. Without a 
detailed understanding of these mechanisms, it will remain impossible to predict potentially 
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hazardous OATP-mediated drug-drug or drug-food interactions, or potentially beneficial 
interactions with small molecules. The studies presented in this dissertation were designed to 
address this lack of understanding by characterizing the mechanism of drug-drug interactions at 
OATP1B1 and OATP1B3. To do this, I formulated the central hypothesis that OATP1B1 and 
OATP1B3 have overlapping but distinct binding sites, which are affected in substrate-dependent 
ways. This hypothesis was based on recent studies that suggest these liver-specific OATPs 
contain multiple substrate binding sites. Experiments in our laboratory have demonstrated that 
mutations in OATPs have varied effects on the transport of different substrates, and that small 
molecules can stimulate, inhibit, or have no effect on OATP1B1 or OATP1B3 function, 
depending upon the substrate transported. This hypothesis was tested via two specific aims: the 
identification and characterization of plant compounds that have substrate-dependent effects on 
OATP1B-mediated transport, and the identification of regions of OATP1B3 that are involved in 
the recognition and translocation of individual model substrates. 
 
 
6.2: Specific Aim 1 
 
In the first specific aim, I screened a small library of plant extracts to identify plant 
compounds that have substrate-dependent effects on OATP-mediated transport. Initial screens 
identified two plant extracts that had similar substrate-dependent effects on OATP1B3-mediated 
transport: Camellia sinensis and Rollinia emarginata Schlecht (Annonaceae). These plant 
extracts were fractionated using a bioassay-guided approach, and the active compounds were 
identified. The substrate-dependent effects on OATP1B3-mediated transport were then 
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characterized by determining how the kinetic parameters of substrate transport were altered in 
the presence of the modifying compound. 
 
The leaves and leaf buds of Camellia sinensis are used in making tea. Initial fractionation 
of this plant extract demonstrated that the substrate dependent stimulation of OATP1B3-
mediated transport caused by the whole plant extract was due to the fraction containing 
catechins. The catechins found in tea include epicatechin (EC), epigallocatechin (EGC), 
epicatechin gallate (ECG) and epigallocatechin gallate (EGCG). Green tea is characterized by 
very high concentrations of catechins, and is a very commonly consumed beverage that has 
received much attention for its reputed health benefits. The most predominant catechin in green 
tea, EGCG, is widely considered responsible for many of the beneficial actions of green tea. Due 
to this, catechin and EGCG supplements are also widely used. The widespread consumption of 
green tea or catechin-containing supplements makes the possibility of drug-food interactions 
very high. Therefore, in addition to characterizing the substrate-dependent alterations of 
OATP1B3-mediated transport, I studied the effect of all four catechins on transport mediated by 
the four OATPs expressed at the apical membrane of enterocytes (OATP1A2 and OATP2B1) or 
the basolateral membrane of hepatocytes (OATP1B1, OATP1B3, and OATP2B1). 
 
This study showed that, while EC and EGC have little effect on OATPs, the larger 
gallated catechins (ECG and EGCG) do significantly alter transport by all four OATPs 
investigated. Both compounds inhibit transport of estrone-3-sulfate by OATP1A2, OATP1B1, 
and OATP2B1 at physiologically relevant concentrations, indicating a significant risk of adverse 
drug-food interactions. EGCG was identified as the compound responsible for the substrate-
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dependent effects on OATP1B3 caused by Camellia sinensis extract in the initial screening. 
EGCG stimulates transport of estrone-3-sulfate, inhibits transport of Fluo-3, and has no effect on 
transport of estradiol-17β-glucuronide. The stimulation of estrone-3-sulfate transport was shown 
to be caused by an increase in substrate affinity (reduced Km), although the maximal rate of 
transport (Vmax) was decreased for both estrone-3-sulfate and Fluo-3. Therefore, EGCG non-
competitively inhibits transport of multiple substrates by OATP1B3, but only alters the affinity 
for certain substrates. This strongly indicates that estrone-3-sulfate does not share a single 
binding site on OATP1B3 with either estradiol-17β-glucuronide or Fluo-3.  
 
As a final step in this study, I tested whether ECG or EGCG were substrates of the four 
OATPs expressed in the intestine or liver. Although there was no significant transport of either 
catechin by OATP1B1 or OATP2B1, both catechins were substrates of OATP1A2 and 
OATP1B3. The uptake was characterized, and it was found that the Michaelis-Menten constants 
(Km) were within the range of physiological exposure, indicating that OATP-mediated uptake 
into enterocytes or hepatocytes could be responsible for the absorption and first-pass clearance of 
catechins. The identification of EGCG as a substrate of OATP1B3 further complicates the 
analysis of its ability to stimulate OATP1B3-mediated transport of certain substrates. It is not 
uncommon for a substrate to increase transport of another substrate through trans-stimulation. 
However, this type of stimulation is characterized by an increased maximal rate of transport. As 
EGCG caused a decrease in the maximal rate of transport, trans-stimulation cannot be 
responsible for the increased uptake of estrone-3-sulfate. Rather, it seems likely that the binding 
of EGCG to OATP1B3 causes a conformational change in the estrone-3-sulfate binding site that 
increases its affinity for estrone-3-sulfate, indicating that the EGCG and estrone-3-sulfate 
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binding sites are distinct. In addition, the inhibitory effect of EGCG on Fluo-3 uptake was found 
to be non-competitive, indicating that EGCG also has a distinct binding site from Fluo-3. This 
part of my first specific aim therefore strongly suggests that OATP1B3 has at least three distinct 
substrate binding sites, and that these sites may be altered in different ways by the same 
compound. 
 
In the second part of my first specific aim, I identified the compounds in Rollinia 
emarginata Schlecht (Annonaceae) that are responsible for substrate-dependent effects on 
OATP1B1 or OATP1B3-mediated transport. Two compounds, ursolic acid and oleanolic acid, 
inhibited OATP1B3-mediated uptake of estrone-3-sulfate while having no effect on estradiol-
17β-glucuronide uptake. Unfortunately, OATP1B3 has relatively low affinity for estrone-3-
sulfate (Km = 60 – 100 µM), and transport was not inhibited by either compound at substrate 
concentrations over 25 µM. This made it impossible to identify any effect on the kinetic 
characteristics of estrone-3-sulfate transport. As both compounds inhibit estrone-3-sulfate uptake 
only at low substrate concentrations, and have no effect on the maximal rate of transport, it 
seems likely that this inhibition is competitive. If this is the case, the identification of 
competitive inhibitors of OATP1B3-mediated estrone-3-sulfate transport that have no effect on 
estradiol-17β-glucuronide transport would be further evidence that the two substrates have 
distinct binding sites on OATP1B3. However, this is merely speculative, as both compounds 
were too weak of inhibitors to be fully characterized. 
 
The other compound identified from Rollinia emarginata Schlecht (Annonaceae) had 
very similar effects to EGCG on OATP1B3-mediated transport. While uptake of estradiol-17β-
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glucuronide was unaffected by EGCG, this transport was inhibited by quercetin 3-Ο-α-L-
arabinopyranosyl (1→2) α-L-rhamnopyranoside (Compound 6). As was seen with EGCG 
inhibition of Fluo-3 transport, this inhibition was non-competitive, causing a decrease in the 
maximal rate of transport without affecting the substrate affinity. As was the case with EGCG, 
Compound 6 also stimulated estrone-3-sulfate uptake by OATP1B3 at low substrate 
concentrations due to increased substrate affinity. At high substrate concentrations, estrone-3-
sulfate transport was non-competitively inhibited. Inclusion of 50 µM EGCG or Compound 6 
increased the affinity for estrone-3-sulfate by five- to ten-fold. However, the maximal rate of 
transport was decreased to less than 20% in the presence of EGCG, while it was only reduced by 
half in the presence of Compound 6.  
 
Both parts of my first specific aim clearly demonstrate that OATP1B3 has overlapping 
but distinct binding sites, which are affected in substrate-dependent ways. OATP1B3 transport of 
estradiol-17β-glucuronide is inhibited by ursolic acid, oleanolic acid, and 8-trans-p-
coumaroyloxy-α-terpineol, while the uptake of estrone-3-sulfate is unaffected by these 
compounds, indicating that the binding sites on OATP1B3 for estradiol-17β-glucuronide and 
estrone-3-sulfate are distinct. OATP1B3 transport of estradiol-17β-glucuronide, estrone-3-
sulfate, and Fluo-3 is altered in different ways by both Compound 6 and EGCG, which is also an 
OATP1B3 substrate, indicating the presence of at least three distinct binding sites on this 
transporter protein. 
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6.3: Specific Aim 2 
 
As the first specific aim indicated that OATP1B3 does have distinct binding sites for 
estradiol-17β-glucuronide and estrone-3-sulfate, in the second specific aim I tested the 
hypothesis that the first transmembrane domain (TM) and extracellular loop (ECL) of OATP1B3 
are involved in the binding and translocation of these two substrates. Thirty-three amino acids 
predicted to form this region of the protein were individually mutated to cysteines, and mutant 
proteins were transiently expressed in HEK293 cells. All of the mutant proteins were fully 
expressed on the surface of the cells, indicating that any changes in transport activity were due to 
alterations in substrate binding or translocation. Many of the mutant proteins showed altered 
functionality, due both to the mutation itself and to alteration of the inserted protein with the 
cysteine-specific reagent sodium (2-sulfonatoethyl)methanethiosulfonate (MTSES). 
 
Mutating two amino acids, I46 and I47, to cysteines resulted in substrate-dependent 
alterations in transporter function. Uptake of estrone-3-sulfate was significantly increased by the 
I47C mutation when compared to the wild-type protein; however, uptake of estradiol-17β-
glucuronide remained unchanged. Whereas uptake of estrone-3-sulfate was the same when 
mediated by either wild-type OATP1B3 or the I46C mutant, uptake of estradiol-17β-glucuronide 
was increased. Similarly, after incubation with the cysteine-modifying MTSES, four of the 
mutants (A42C, G45C, I46C and I52C) had significantly greater loss of transport activity for 
estradiol-17β-glucuronide than for estrone-3-sulfate. 
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Analysis of the functional effect of mutations, both before and after MTSES 
modification, and of the extracellular accessibility of the mutations, indicates that the first 
transmembrane domain of OATP1B3 forms part of the external portion of the substrate 
translocation pore. The substrate-dependent effects of cysteine insertion suggest that the 
interactions between TM1 and estradiol-17β-glucuronide are different than the interactions 
between TM1 and estrone-3-sulfate. 
 
6.4: Future Directions 
 
The studies in my first specific aim demonstrated that OATP1B3 activity can be 
stimulated, inhibited, or unaffected by the same compound, depending on the substrate 
transported. Substrate-selective inhibition or stimulation has the potential to improve drug 
therapies without the possible attendant toxicity of altering transport of endogenous substrates. 
Identifying the mechanism of substrate-dependent stimulation is of particular interest, as this 
could be harnessed to increase OATP1B3-mediated uptake of anticancer drugs into OATP1B3-
expressing cancer cells. Two approaches can be taken to investigate the mechanism of this 
stimulation: identification of the structural requirements for stimulating compounds, and 
determination of the regions of OATP1B3 that are responsible for interacting with the 
stimulators. 
 
The first specific aim identified plant compounds as a rich source of OATP modulating 
compounds, and showed that the approach of bioassay guided fractionation is an efficient way to 
isolate stimulators of OATP1B3-mediated transport. By using this approach to screen the large 
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library of plant extracts at the Department of Medicinal Chemistry, University of Kansas, it 
should be possible to identify a significant number of compounds that have this stimulating 
effect. Preliminary studies have already identified a compound from Asclepias syriaca, 3-Ο-α-L-
xylopyranosyl(1→2)β-D-galactopyranoside, that stimulates estrone-3-sulfate uptake by 
OATP1B3. As with EGCG and quercetin 3-Ο-α-L-arabinopyranosyl (1→2) α-L-
rhamnopyranoside (Compound 6), uptake of estrone-3-sulfate is stimulated at low substrate 
concentrations due to an increased substrate affinity, whereas the maximal rate of transport is 
inhibited. The screening has also identified many structurally related compounds that do not 
stimulate OATP1B3-mediated uptake of estrone-3-sulfate. Once enough compounds have been 
identified, a comparative structural analysis of the stimulating and non-stimulating compounds 
will identify the structural components necessary for this stimulation.  
 
A transporter-centered approach can also be used to identify the mechanism of OATP1B3 
stimulation. As transport of estrone-3-sulfate by OATP1B1 is not stimulated by the OATP1B3-
stimulating compounds, chimeras between these two closely related proteins can be used to 
identifying the regions of OATP1B3 that are involved in this stimulation. Our laboratory has 
previously generated chimeras that contain a single transmembrane domain of OATP1B1 
inserted into OATP1B3, and chimeras that contain single transmembrane domains of OATP1B3 
inserted into OATP1B1. By measuring estrone-3-sulfate uptake by these chimeric proteins in the 
absence and presence of OATP1B3-stimulating compounds, we may be able to identify regions 
of OATP1B3 that directly interact with the stimulators. Once regions have been defined, 
individual amino acids involved in the interaction can be identified through site-directed 
mutagenesis experiments. 
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My second specific aim identified the first transmembrane domain and extracellular loop 
as being involved in substrate-specific interactions with estradiol-17β-glucuronide and estrone-3-
sulfate. This study resulted in many interesting observations that could be followed up with 
further studies. As mentioned, substitution of residues I46 and I47 with cysteines resulted in 
substrate-specific alterations, with I46C showing increased uptake of estradiol-17β-glucuronide 
and I47C having increased uptake of estrone-3-sulfate (Figure 5-3). Analysis of the kinetic 
parameters of substrate uptake by these two mutants could reveal whether this increased uptake 
is due to increased substrate affinity or increased turnover rate. If the effects are caused by 
altered substrate affinity, this would suggest that the two substrates bind to slightly different 
regions of TM1 in OATP1B3. 
 
This study also confirmed previous research showing that positive charges located within 
the substrate translocation pore are important for OATP-mediated transport of model substrates. 
Uptake of both substrates was almost completely abrogated by substitution of cysteine for the 
positively charged K41. Mutating this residue to the neutral amino acids alanine or glutamine 
resulted in similarly non-functional proteins. However, mutating K41 to another positively 
charged amino acid, arginine, restored full transport activity, indicating that a positive charge in 
this location is essential for OATP1B3 function. Similar results were shown in a recent 
publication (Mandery et al., 2011). The importance of positive charges was also demonstrated by 
the R58C mutation. Substituting cysteine for the positively charged arginine caused a 50% 
reduction in function (Figure 5-3). Modifying this amino acid with the negatively charged 
MTSES resulted in a nearly non-functional protein, which retained only 15% of the already 
reduced function (Figure 5-4). However, modifying the R58C protein with the positively charged 
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reagent [2-(trimethylammonium)ethyl] methanethiosulfonate bromide (MTSET) increased the 
uptake of both substrates by 50 to 100% (data not shown). This demonstrates that positive 
charges both within the substrate translocation pore and in the extracellular domain are important 
for recognition and translocation of anionic model substrates. Again, determination of the kinetic 
characteristics of these mutants would help define the mechanism of these interactions. 
Additionally, it would be valuable to learn whether the importance of these positive charges is 
restricted to the transport of anionic substrates, or whether the same results would be seen when 
measuring uptake of neutral or cationic OATP1B3 substrates. 
 
Finally, many of the amino acids found to be important for substrate binding and/or 
translocation were labeled by maleimide-PEG2-biotin (Figure 5-5). If these amino acids do 
interact with the substrates, incubating the mutant proteins with substrate should protect the 
inserted cysteine from maleimide-PEG2-biotin labeling. Preliminary experiments suggest that 
this does occur for the mutants A42C, I46C and M48C. However, this only occurs after a pre-
incubation with estradiol-17β-glucuronide, not after incubation with estrone-3-sulfate. 
Confirmation of these results would indicate that binding of estradiol-17β-glucuronide to 
OATP1B3 either directly covers this region of the first transmembrane domain, or causes a 
conformational change that prevents maleimide-PEG2-biotin from interacting with the inserted 
cysteines. As estrone-3-sulfate pre-incubation does not produce the same effect, this would be 
evidence that the two substrates either interact with different protein regions, or result in 
different conformational changes of the protein. 
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Further studies as discussed above are essential to determine the mechanism of the 
substrate-dependent effects on OATP1B3-mediated transport. This increased understanding will 
improve our ability to predict potentially hazardous OATP-mediated drug-drug or drug-food 
interactions prior to the occurrence of adverse events. Additionally this knowledge may allow for 
the manipulation of drug-drug or drug-small molecule interactions in a way that would improve 
drug pharmacokinetics or target anticancer drugs to cancer cells.  
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